ࡱ> o bjbjVV (4zf4zfOy>>d!!!0'.!Od?6?6<<<V V V$i~QVRRVV<< y~y~y~V<<y~Vy~y~DΛ<0p0b&~0OFqLΛΛ,VVy~VVVVVxVVVOVVVVVVVVVVVVV> I: This section lists the codes and units for contract drugs. For additional help, refer to the Drugs: Contract Drugs List Introduction section of this manual. * NABUMETONE * Restricted to use for arthritis. Tablets 500 mg ea 750 mg ea Note: Subject to Step Therapy edits. See Drugs: Contract Drugs List Part 8 Step Therapy for more information. NAFCILLIN Powder for injection 500 mg/vial ea 1 gm/vial ea 2 gm/vial ea 10 gm/vial ea 1 gm, piggyback ea 2 gm, piggyback ea * NAFTIFINE HCL * Restricted to claims with dates of service from October 1, 2005, through November 30, 2011, for all dosage forms. Topical Cream 1 % 15 gm gm 30 gm gm 60 gm gm 90 gm gm Topical Gel 1 % 20 gm gm 40 gm gm 60 gm gm 90 gm gm NALIDIXIC ACID Tablets 250 mg ea 500 mg ea 1 gm ea Note: These products are no longer manufactured or available. Effective March 1, 2017 NAL * NALOXEGOL OXALATE * Restricted to use in the treatment of opioid-induced constipation in patients with chronic pain. Also restricted to NDC labeler code 00310 (AstraZeneca LP). Tablets 12.5 mg ea 25 mg ea NALOXONE HCL Injection 0.4 mg/ml ml 1.0 mg/ml ml Intranasal Spray 4.0 mg/0.1 ml ea NALTREXONE HCL Restricted to use in the treatment of alcohol dependence and for the prevention of relapse in opioid dependent patients, following opioid detoxification. Restricted to prescription only by prescribers trained in substance use disorder treatment. Restricted to a maximum dispensing quantity of 100 tablets and a maximum of three (3) dispensings in any 75-day period. Tablets 50 mg ea NAPHAZOLINE HCL Ophthalmic solution 0.1 % ml NAPHAZOLINE HCL AND ANTAZOLINE PHOSPHATE Ophthalmic solution 0.05 % 0.5% ml NAPROXEN + Tablets or capsules 250 mg ea 375 mg ea 500 mg ea Liquid 125 mg 5 ml ml Note: Subject to Step Therapy edits. See Drugs: Contract Drugs List Part 8 Step Therapy for more information. Effective June 1, 2019 NAT NATAMYCIN Ophthalmic suspension 5 % 15 ml ml NATEGLINIDE + Tablets 60 mg ea 120 mg ea * NECITUMUMAB * Restricted to use in the treatment of cancer only. Also restricted to labeler code 00002 (Eli Lilly and Company) only. Injection 800 mg/50 ml ml * NELFINAVIR MESYLATE * Restricted to use as combination therapy in the treatment of Human Immunodeficiency Virus (HIV) infection. Tablets 250 mg ea 625 mg ea Oral powder 50 mg/gm gm NELARABINE Injection 5 mg/ml ml NEOMYCIN Tablets 0.5 gm ea Liquid 125 mg/5ml ml NEOMYCIN, BACITRACIN AND POLYMYXIN Ophthalmic ointment gm NEOMYCIN AND POLYMYXIN Ampule G.U. Irrigant ml NEOMYCIN, POLYMYXIN AND GRAMICIDIN Ophthalmic solution ml Effective January 1, 2017 NEO NEOSTIGMINE BROMIDE + Tablets 15 mg ea Note: This product is no longer manufactured or available. NEPAFENAC Ophthalmic suspension * 0.1 % ml * Restricted to claims submitted with dates of service from August 1, 2005, through March 31, 2015, for the 0.1% only. * 0.3 % ml * Restricted to the 3 ml bottle size only. The 1.7ml bottle size is restricted to claims submitted with dates of service from October 1, 2013, through February 29, 2020, for the 0.3% suspension only. * NETARSUDIL * Restricted to labeler code 70727 (Aerie Pharmaceuticals, Inc.). Ophthalmic solution 0.02 % ml * NETARSUDIL/LATANOPROST * Restricted to labeler code 70727 (Aerie Pharmaceuticals, Inc.). Ophthalmic solution 0.02 %/0.005 % ml Effective March 1, 2020 NEV * NEVIRAPINE * Restricted to use as combination therapy in the treatment of Human Immunodeficiency Virus (HIV) infection. Tablets 200 mg ea Tablets extended-release 100 mg ea Restricted to NDC labeler code 00597 (Boehringer Ingelheim Pharmaceuticals) for the 100 mg extended-release tablets only. 400 mg ea Liquid * 50 mg/5 ml ml * Restricted to NDC labeler code 00597 (Boehringer Ingelheim Pharmaceuticals) for the 50 mg/5 ml liquid only. NIACIN Tablets, extended release 500 mg ea (includes film coated tablets) 750 mg ea 1000 mg ea NIACIN AND LOVASTATIN Tablets (containing extended release niacin) 500 mg/20 mg ea 750 mg/20 mg ea 1000 mg/20 mg ea 1000 mg/40 mg ea Note: These products are no longer manufactured or available. Effective July 1, 2020 NIA * NIACIN AND SIMVASTATIN * Restricted to NDC labeler code 00074 (Abbott Laboratories) only. Tablets (containing extended release niacin) 500 mg/20 mg ea 500 mg/40 mg ea 750 mg/20 mg ea 1000 mg/20 mg ea 1000 mg/40 mg ea Note: These products are no longer manufactured or available. NICARDIPINE + Capsules 20 mg ea 30 mg ea + Tablets or capsules, long-acting 30 mg ea 45 mg ea 60 mg ea NICLOSAMIDE Tablets 500 mg ea Note: This product is no longer manufactured or available. NIFEDIPINE + Capsules 10 mg ea 20 mg ea + Tablets or capsules long-acting 30 mg ea 60 mg ea 90 mg ea * NILOTINIB * Restricted to use in the treatment of cancer only for all strengths. Also restricted to NDC labeler code 00078 (Novartis Pharmaceuticals Corporation) only. Capsules 150 mg ea 200 mg ea NIL * NILUTAMIDE * Restricted to use in the treatment of cancer only. Tablets 150 mg ea * NIRAPARIB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 69656 (TESARO Inc.) only. Capsules 100 mg ea NISOLDIPINE Tablets 8.5 mg ea * 10 mg ea 17 mg ea * 20 mg ea 25.5 mg ea * 30 mg ea 34 mg ea * 40 mg ea * Restricted to claims with dates of service from March 1, 1997, through March 31, 2010, for the 10 mg, 20 mg, 30 mg and 40 mg tablets only. NITROFURANTOIN Capsules (macrocrystals only) 25 mg ea 50 mg ea 100 mg ea Capsules (monohydrate/macrocrystals) 100 mg ea Tablets 50 mg ea 100 mg ea Liquid 5 mg/ml ml NIT NITROGLYCERIN (GLYCERYL TRINITRATE) + Tablets (sublingual) (no long-acting forms) 0.15 mg ea 0.3 mg ea 0.4 mg ea 0.6 mg ea Ointment 2 % 20 gm gm 30 gm gm 60 gm gm Spray, lingual 12 gm gm * NIVOLUMAB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00003 (E. R. Squibb & Sons, Inc.) only. Injection 40 mg/4 ml ml 100 mg/10 ml ml 240 mg/24 ml ml * NORELGESTROMIN AND ETHINYL ESTRADIOL * Restricted to a maximum dispensing quantity of up to 52 patches per client. The maximum quantity is intended for clients on a continuous cycle. A 12-month supply of the same product of contraceptive patches may be dispensed twice in one year. A Treatment Authorization Request (TAR) is required for the third supply of up to 12 months of the same product requested within a year. Transdermal patch 6 mg 0.75 mg ea 4.86 mg 0.53 mg ea Note: Payment limited to a minimum dispensing quantity of three cycles except with the initial prescription or when authorization is obtained. NOR * NORETHINDRONE * Restricted to a maximum quantity of up to 18 cycles (packs) per dispensing. The maximum supply is intended for clients on continuous cycle. A 12-month supply of the same product of oral contraceptive may be dispensed twice in one year. A Treatment Authorization Request (TAR) is required for the third supply of up to 12 months of the same product requested within a year. Tablets 0.35 mg Tablets from 28 tablet packet ea Tablets from 42 tablet packet ea Note: Payment limited to a minimum dispensing quantity of three cycles. See California Code of Regulations (CCR), Title 22, Section 51513(b)(4) regarding exceptions. * NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL * Restricted to a maximum quantity of up to 18 cycles (packs) per dispensing. The maximum supply is intended for clients on continuous cycle. A 12-month supply of the same product of oral contraceptive may be dispensed twice in one year. A Treatment Authorization Request (TAR) is required for the third supply of up to 12 months of the same product requested within a year. Tablets 1 mg-5mcg ea Tablets * 1 mg 10 mcg/2 Fe tablets Tablets from 28 tablet packet ea * Restricted to NDC Labeler Code 00430 (Warner Chilcott Laboratories) only. 1 mg 20 mcg Tablets from 21 tablet packet ea 1 mg 20 mcg/7 Fe tablets Tablets from 28 tablet packet ea Tablets 1.5 mg 30 mcg Tablets from 21 tablet packet ea 1.5 mg 30 mcg/7 Fe tablets Tablets from 28 tablet packet ea Tablets from 5/7/9 combination packet (28 Tablets/packet) 5 x 1 mg/20 mcg 7 x 1 mg/30 mcg 9 x 1 mg/35 mcg 7 inert ea Note: Payment limited to a minimum dispensing quantity of three cycles. See California Code of Regulations (CCR), Title 22, Section 51513(b)(4) regarding exceptions. Suspended until further notice NOR (continued) * NORETHINDRONE AND ETHINYL ESTRADIOL * Restricted to a maximum quantity of up to 18 cycles (packs) per dispensing. The maximum supply is intended for clients on continuous cycle. A 12-month supply of the same product of oral contraceptive may be dispensed twice in one year. A Treatment Authorization Request (TAR) is required for the third supply of up to 12 months of the same product requested within a year. Tablets 0.4 mg 35 mcg Tablets from 21 tablet packet ea Tablets from 28 tablet packet ea 0.5 mg 35 mcg Tablets from 21 tablet packet ea Tablets from 28 tablet packet ea 1 mg 35 mcg Tablets from 21 tablet packet ea Tablets from 28 tablet packet ea 1 mg 50 mcg Tablets from 21 tablet packet ea Tablets from 28 tablet packet ea Note: 1 mg 50 mcg product is no longer manufactured or available. Tablets from 7/7/7 combination packet Tablets from 21 tablet packet Tablets from 28 tablet packet 7 x 0.5 mg/35 mcg 7 x 0.75 mg/35 mcg 7 x 1.0 mg/35 mcg ea Tablets from 7/9/5 combination packet Tablets from 21 tablet packet Tablets from 28 tablet packet 7 x 0.5 mg/35 mcg 9 x 1.0 mg/35 mcg 5 x 0.5 mg/35 mcg ea NOR (continued) * NORETHINDRONE AND ETHINYL ESTRADIOL (continued) Tablets from 10/11 combination packet Tablets from 21 tablet packet Tablets from 28 tablet packet 10 x 0.5 mg/35 mcg 11 x 1 mg/35 mcg ea Tablets from 7/14 combination packet (28 tablets/packet) 7 x 0.5 mg/35 mcg 14 x 1 mg/35 mcg 7 inert ea Note: 7/14 combination packet is no longer manufactured or available. Note: Payment limited to a minimum dispensing quantity of three cycles. See California Code of Regulations (CCR), Title 22, Section 51513(b)(4) regarding exceptions. * NORETHINDRONE AND MESTRANOL * Restricted to a maximum quantity of up to 18 cycles (packs) per dispensing. The maximum supply is intended for clients on continuous cycle. A 12-month supply of the same product of oral contraceptive may be dispensed twice in one year. A Treatment Authorization Request (TAR) is required for the third supply of up to 12 months of the same product requested within a year. Tablets 1 mg-50 mcg Tablets from 21 tablet packet ea Tablets from 28 tablet packet ea Note: Payment limited to a minimum dispensing quantity of three cycles. See California Code of Regulations (CCR), Title 22, Section 51513(b)(4) regarding exceptions. NORFLOXACIN Tablets or capsules 400 mg ea Note: These products are no longer manufactured or available. NOR (continued) * NORGESTIMATE AND ETHINYL ESTRADIOL * Restricted to a maximum quantity of up to 18 cycles (packs) per dispensing. The maximum supply is intended for clients on continuous cycle. A 12-month supply of the same product of oral contraceptive may be dispensed twice in one year. A Treatment Authorization Request (TAR) is required for the third supply of up to 12 months of the same product requested within a year. Tablets from 7/7/7 (tri-phasic) combination packet (21 tablets/packet) 7 x 0.180 mg/35 mcg 7 x 0.215 mg/35 mcg 7 x 0.250 mg/35 mcg ea Tablets from 7/7/7 (tri-phasic) combination packet (28 tablets/packet) 7 x 0.180 mg/35 mcg 7 x 0.215 mg/35 mcg 7 x 0.250 mg/35 mcg 7 x inert ea Tablets from monophasic packet (28 tablets/packet) 21 x 0.25 mg/35 mcg 7 x inert ea Note: Payment limited to a minimum dispensing quantity of three cycles. See California Code of Regulations (CCR), Title 22, Section 51513(b)(4) regarding exceptions. * NORGESTREL AND ETHINYL ESTRADIOL * Restricted to a maximum quantity of up to 18 cycles (packs) per dispensing. The maximum supply is intended for clients on continuous cycle. A 12-month supply of the same product of oral contraceptive may be dispensed twice in one year. A Treatment Authorization Request (TAR) is required for the third supply of up to 12 months of the same product requested within a year. Tablets 0.3mg 30 mcg Tablets from 21 tablet packet ea Tablets from 28 tablet packet ea 0.5mg 50 mcg Tablets from 21 tablet packet ea Tablets from 28 tablet packet ea Note: Payment limited to a minimum dispensing quantity of three cycles. See California Code of Regulations (CCR), Title 22, Section 51513(b)(4) regarding exceptions. NOR (continued) * NORTRIPTYLINE HCL * Use in beneficiaries less than 18 years of age requires treatment authorization approval. Capsules 10 mg ea 25 mg ea 50 mg ea 75 mg ea Liquid 10 mg/5 ml ml NYSTATIN Tablets (oral) 500,000 units ea Suspension, oral 100,000 units/ml 48 ml ml 60 ml ml 480 ml ml Vaginal tablets 15s ea 30s ea Cream 100,000 units/gm 15 gm gm 100,000 units/gm 30 gm gm Ointment 100,000 units/gm 15 gm gm 100,000 units/gm 30 gm gm 240 gm gm Topical powder gm * OBINUTUZUMAB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 50242 (Genentech, Inc.) only. Injection 25 mg/ml ml * OFATUMUMAB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00078 (Novartis Pharmaceuticals Corporation) or 00173 (GlaxoSmithKline) only. Injection 100 mg/5 ml ml 1000 mg/50 ml ml OFL OFLOXACIN Ophthalmic solution 0.3 % ml Otic solution 0.3 % 5 ml ml 10 ml ml * Tablets 200 mg ea 300 mg ea 400 mg ea * Restricted to use in the treatment of sexually transmitted diseases. * OLANZAPINE * Restricted to: 1) The use of antipsychotics for Medi-Cal beneficiaries less than 18 years of age requires treatment authorization approval; 2) The use of antipsychotics for Medi-Cal beneficiaries residing in nursing facilities is restricted to FDA approved indications. Tablets 2.5 mg ea 5 mg ea 7.5 mg ea 10 mg ea 15 mg ea 20 mg ea Tablets, orally disintegrating 5 mg ea 10 mg ea 15 mg ea 20 mg ea * OLAPARIB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00310 (AstraZeneca LP) only. Capsule 50 mg ea Tablets 100 mg ea 150 mg ea OLA * OLARATUMAB * Restricted to use in the treatment of cancer only. Also restricted to labeler code 00002 (Eli Lilly and Company) only. Injection 500 mg/50 ml ml 190 mg/19 ml ml OLMESARTAN MEDOXOMIL + Tablets * 20 mg ea * 40 mg ea * Restricted to claims with dates of service from April 1, 2003, through May 31, 2008, only. * OLMESARTAN MEDOXOMIL/HYDROCHLOROTHIAZIDE * Restricted to claims with dates of service from November 1, 2007, through May 31, 2008, only. + Tablets 20 mg 12.5 mg ea 40 mg 12.5 mg ea 40 mg 25 mg ea * OLOPATADINE HCL * Restricted to NDC labeler code 00065 (Alcon Laboratories, Inc.) only. Ophthalmic solution * 0.1 % ml * 0.2 % ml * Restricted to claims with dates of service through June 30, 2016, for the ophthalmic solutions 0.1% and 0.2%. 0.7 % ml Nasal spray 0.6 % gm * OMACETAXINE MEPESUCCINATE * Restricted to use in the treatment of cancer only and to NDC labeler code 63459 (Cephalon, Inc.) only. Powder for injection 3.5 mg ea Effective July 1, 2019 OMB * OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR * Requires a Treatment Authorization Request (TAR). Restricted to use in the treatment of chronic Hepatitis C Virus (HCV) infection in adults (e"18 years of age). Also restricted to 1) a maximum quantity of 112 tablets per dispensing; and 2) duration of therapy lasting up to 12 or 24 weeks from the dispensing date of the first prescription. Tablets (dose-pack) 12.5 mg/75 mg/50 mg; 250 mg ea Note: Providers must provide documentation of baseline HCV-RNA level and HCV genotype. In addition, when applicable, providers must document relevant clinical information (i.e., failure of prior treatment, presence of cirrhosis, etc.) in support of medical necessity for duration of therapy. Failure to submit supporting documentation may delay authorization of the TAR. Note: ea means tablet. * OMBITASVIR/PARITAPREVIR/ RITONAVIR/DASABUVIR * Requires a Treatment Authorization Request (TAR). Restricted to use in the treatment of chronic Hepatitis C Virus (HCV) infection in adults (e"18 years of age). Also restricted to 1) a maximum quantity of 84 tablets per dispensing; and 2) duration of therapy lasting up to 12 or 24 weeks from the dispensing date of the first prescription. Tablets, extended-release (dose-pack) 8.33 mg/50 mg/33.33 mg/200 mg ea Note: Providers must provide documentation of baseline HCV-RNA level and HCV genotype. In addition, when applicable, providers must document relevant clinical information (i.e., failure of prior treatment, presence of cirrhosis, etc.) in support of medical necessity for duration of therapy. Failure to submit supporting documentation may delay authorization of the TAR. Note: ea means tablet. OME OMEPRAZOLE Capsules, delayed release 10 mg ea 20 mg ea 40 mg ea * OMEPRAZOLE/SODIUM BICARBONATE * Restricted to claims with dates of service from August 1, 2005, through September 30, 2009, only. Powder packet 20 mg ea 40 mg ea Capsules 20 mg ea 40 mg ea ONDANSETRON + * Injection 2 mg/ml 2 ml ml * Restricted to a maximum of 16 mg per dispensing for the injection only. + Tablets 4 mg ea 8 mg ea + Tablets, orally disintegrating 4 mg ea 8 mg ea OPRELVEKIN Powder for injection 5 mg/vial ea Note: This product is no longer manufactured or available. OSELTAMIVIR PHOSPHATE Capsules 30 mg ea 45 mg ea 75 mg ea Oral suspension 6 mg/ml 60 ml ml Effective May 1, 2019 OSI * OSIMERTINIB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00310 (AstraZeneca LP) only. Tablets 40 mg ea 80 mg ea * OXALIPLATIN * Restricted to use in the treatment of cancer only. Injection 5 mg/ml ml OXANDROLONE * Tablets 2.5 mg ea * Restricted to use in patients with AIDS wasting for claims submitted with dates of service from March 1, 2001, through May 31, 2003. * Tablets 10 mg ea * Authorization required for claims submitted with dates of service on or after September 1, 2002. * OXCARBAZEPINE * Use in beneficiaries less than 2 years of age requires treatment authorization approval. Tablets 150 mg ea 300 mg ea 600 mg ea * OXICONAZOLE NITRATE * Restricted to NDC labeler code 00462 (PharmaDerm) only with dates of service through November 30, 2012, for all dosage forms. Cream 1 % 15 gm gm 30 gm gm 60 gm gm Lotion 1 % 30 ml ml OXY * OXYBUTYNIN * Restricted to NDC labeler codes 52544 (Watson Laboratories, Inc.) and 00023 (Allergan, Inc.) only. Transdermal system 3.9 mg ea OXYBUTYNIN CHLORIDE + Tablets 5 mg ea * + Tablets, extended release 5 mg ea 10 mg ea 5 mg ea * Restricted to NDC labeler code 17314 (Alza Corporation) and to claims submitted with dates of service from December 1, 1998, through December 31, 2008, for extended release tablets only. * OXYCODONE AND ACETAMINOPHEN * Restricted to a maximum quantity per dispensing of20 tablets or capsules ninety (90) tablets and a maximum of three (3) dispensings in any 75-day period. Tablets or capsules 5 mg 500 mg ea 5 mg 325 mg ea 7.5 mg 325 mg ea 10 mg 325 mg ea Note: 5 mg 500 mg is no longer manufactured or available. Effective August 1, 2020 OXY (continued) OXYCODONE HCL * Tablets or capsules 5 mg ea 15 mg ea 30 mg ea * Restricted to a maximum of 90 tablets or capsules per dispensing and one dispensing every 25 days. Exceptions to this restriction require authorization. * Tablets, controlled release 10 mg ea 20 mg ea 40 mg ea 80 mg ea 160 mg ea * Restricted to a maximum of 90 tablets per dispensing and a maximum of three (3) dispensings of any strength in a 75-day period and restricted to claims with dates of service from July 1, 1996, through August 31, 2008, only. Exceptions to this restriction require authorization. Solution ml Concentrate ml OXYCODONE HCL AND ASPIRIN * Tablets 4.8355 mg 325 mg ea * Restricted to a maximum dispensing quantity of 120 tablets and a maximum of three (3) dispensings in any 75-day period. * OXYCODONE HCL WITH OXYCODONE TEREPHTHALATE AND ASPIRIN * Restricted to a maximum dispensing quantity of 120 tablets and a maximum of three (3) dispensings in any 75-day period. Tablets 2.25 mg 0.19 mg 325 mg ea 4.5 mg 0.38 mg 325 mg ea Note: These products are no longer manufactured or available. OXY (continued) OXYMORPHONE Ampule 1 mg/ml 1 ml ml 1.5 mg/ml 1 ml ea 10 ml ml Suppositories 5 mg ea PACLITAXEL, SEMI-SYNTHETIC Injection ml * PALBOCICLIB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00069 (Pfizer, Inc.) only. Capsules 75 mg ea 100 mg ea 125 mg ea PALONOSETRON HCL + * Injection 0.25 mg/5 ml ml * Restricted to a maximum of 5 ml per dispensing and to NDC labeler codes 62856 (Eisai, Inc.) only. PAMIDRONATE DISODIUM Powder for injection ea PANCRELIPASE (AMYLASE/LIPASE/PROTEASE) Tablets ea Capsules ea Capsules with enteric coated granules ea Powder gm PAN * PANITUMUMAB * Restricted to use in the treatment of cancer and to claims submitted with dates of service from October 13, 2006, through February 28, 2010, only. Continuing care with a date of service on or after March 1, 2010, is available when the following conditions are met: 1) The beneficiary had a paid fee-for-service claim for this drug on or before February 28, 2010; 2) A claim has been submitted and paid within the past 100 days; and 3) The claim being submitted is within 100 days of the date of service of the last paid claim. Injection 20 mg/ml 5 ml ml 10 ml ml 20 ml ml * PANOBINOSTAT * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00078 (Novartis Pharmaceuticals Corporation) or 00173 (GlaxoSmithKline) only. Capsules 10 mg ea 15 mg ea 20 mg ea PANTOPRAZOLE SODIUM + Tablets, delayed-release 20 mg ea 40 mg ea * PAPAIN AND UREA * Restricted to NDC labeler codes 50484 (Smith & Nephew, Inc.) and 58980 (Stratus Pharmaceuticals) only and with dates of service on or before February 28, 2009. Ointment gm PAP PAPAIN-UREA-CHLOROPHYLLIN COPPER COMPLEX SODIUM * Ointment 30 gm gm * (NDC labeler codes 00064 [Healthpoint, Ltd.] 50484 [Smith & Nephew, Inc.] and 58980 [Stratus Pharmaceuticals] only until April 30, 2006.) * Effective May 1, 2006, NDC labeler codes 50484 [Smith & Nephew, Inc.] and 58980 [Stratus Pharmaceuticals] only and with dates of service on or before February 28, 2009. * Spray 33 ml ml * Restricted to claims submitted with dates of service from January 1, 2004, through April 30, 2006. PAREGORIC Liquid PAREGORIC AND PROTECTIVE Liquid ml PAROMOMYCIN SULFATE Capsules ea * PAROXETINE HCL * Use in beneficiaries less than 18 years of age requires treatment authorization approval. Suspension, oral 10 mg/5ml ml Tablets 10 mg ea 20 mg ea 30 mg ea 40 mg ea * Tablets, controlled release 12.5 mg ea 25 mg ea 37.5 mg ea * Restricted to dates of service from October 1, 2002, through December 31, 2011, for the controlled-release tablets only. Continuing care with a date of service on or after December 31, 2011, is available when the following conditions are met: 1) The beneficiary had a paid fee-for-service claim for this drug on or before December 31, 2011; 2) A claim has been submitted and paid within the past 100 days; and 3) The claim being submitted is within 100 days of the date of service of the last paid claim. PAR * PAROXETINE MESYLATE * Restricted to claims with dates of service from September 1, 2004, through May 31, 2009, only. Tablets 10 mg ea 20 mg ea 30 mg ea 40 mg ea * PAZOPANIB HYDROCHLORIDE * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00078 (Novartis Pharmaceuticals Corporation). Tablets 200 mg ea PEGASPARGASE Injection 750 units/ml ml * PEGINTERFERON ALFA-2A * Restricted to use in the treatment of chronic viral Hepatitis B or C infection. Also restricted to therapy lasting up to 48 weeks from the dispensing date of the first prescription for all dosage forms and strengths and to labeler code 00004 (Roche Laboratories Inc.). * Injection kit with alcohol pads 180 mcg/0.5 ml ea kit * Restricted to a maximum of one injection kit per dispensing for the 180 mcg/0.5 ml injection kit. Injection kit with alcohol pads 180 mcg/0.5 ml is currently no longer manufactured or available and will not be payable after June 30, 2012. * Syringes, package of four, without alcohol pads 180 mcg/0.5 ml ml * Restricted to a maximum of 2 ml per dispensing for the 180 mcg/0.5 ml syringes, package of four, without alcohol pads. PEG * PEGINTERFERON ALFA-2A (continued) * Pen injector, package of four 180 mcg/0.5 ml ml 135 mcg/0.5 ml ml * Restricted to a maximum of 2 ml per dispensing, package of four, for both strengths of the auto injector pens only. * Injection 180 mcg/ml ml * Restricted to a maximum of four vials per dispensing for the 180 mcg/ml injection only. * Injection kit with alcohol pads 180 mcg/ml is currently no longer manufactured or available. Note: Previously, the injection kit (NDC 00004-0352-39) was billed in units of each kit (four 0.5 ml syringes as one kit). As recently as October 2011, new packaging (NDC 00004-0357-30) was released without alcohol pads and therefore is no longer designated as a kit by NCPDP standards. Bill NDC 00004-0357-30 in units of ml (four 0.5 ml syringes, totaling two ml per package). * PEGINTERFERON ALFA-2B * Powder for injection kit 50 mcg/0.5 ml ea 80 mcg/0.5 ml ea 120 mcg/0.5 ml ea 150 mcg/0.5 ml ea * Powder for injection, 50 mcg/0.5 ml ea single dose delivery system 80 mcg/0.5 ml ea 120 mcg/0.5 ml ea 150 mcg/0.5 ml ea * Restricted to use in the treatment of Hepatitis C. Also restricted to a maximum of four injection kits or single dose delivery systems per dispensing and therapy lasting up to 48 weeks from the dispensing date of the first prescription for the powder for injection, single dose delivery system only. Also restricted to labeler code 00085 (Schering Corporation) only. * Lyophilized powder for injection 296 mcg (200 mcg deliverable) ea 444 mcg (300 mcg deliverable) ea 888 mcg (600 mcg deliverable) ea * Restricted to use in the treatment of cancer for the lyophilized powder for injection only. PEM * PEMBROLIZUMAB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00006 (Merck & Company, Inc.) only. Powder for injection 50 mg/vial ea Solution for injection 100 mg/4 ml ml * PEMETREXED * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00002 (Eli Lilly and Company) only. Powder for injection 100 mg/vial ea 500 mg/vial ea * PEMIROLAST POTASSIUM * Restricted to claims with dates of service from December 1, 2000, through September 30, 2010, only. Ophthalmic solution 0.1 % 10 ml ml * PEMOLINE * Restricted to use in Attention Deficit Disorder in individuals from 4 years through 16 years of age with a Medi-Cal fee-for-service paid claim for this drug prior to December 1, 2005, and with the claim being submitted within 100 days of the date of service of the last paid claim submitted. Tablets or capsules 18.75 mg ea 37.5 mg ea 75 mg ea Tablets (chewable) 37.5 mg ea PENBUTOLOL SULFATE + Tablets 20 mg ea PEN PENICILLIN G Powder for injection 1,000,000 units/vial ea 5,000,000 units/vial ea 10,000,000 units/vial ea 20,000,000 units/vial ea PENICILLIN G BENZATHINE Injection 300,000 U/ml 10 ml ml 600,000 U/ml 1 ml ml 2 ml ml 4 ml ml PENICILLIN G PROCAINE Injection ml PENICILLIN V (K) Tablets 125 mg ea 250 mg ea 500 mg ea Liquid 125 mg/5ml 100 ml ml 150 ml ml 200 ml ml 250 mg/5ml 100 ml ml 150 ml ml 200 ml ml PENTAMIDINE Powder for injection 300 mg/vial ea * Powder for aerosolized administration 300 mg/vial ea * Restricted to the prevention of pneumocystis carinii pneumonia (PCP) and must meet all of the following criteria: 1. Patient is HIV-infected, with a history of PCP or with a CD4 (T4) lymphocyte count less than or equal to 200 cells/mm3. 2. Nebulizer system must comply with the specifications in the package insert for the drug product. PEN (continued) PENTOBARBITAL Suppositories 30 mg ea 60 mg ea 120 mg ea 200 mg ea PENTOSAN POLYSULFATE SODIUM Capsules 100 mg ea PENTOSTATIN Powder for injection 10 mg/vial ea * PENTOXIFYLLINE * Restricted to use for patients 65 years of age or older diagnosed with intermittent claudication, or for diabetic patients of any age diagnosed with intermittent claudication. + Tablets or capsules 400 mg ea PERGOLIDE MESYLATE Tablets * 0.05 mg ea * 0.25 mg ea 1.0 mg ea * Restricted to NDC labeler codes 59075 (Elan Pharmaceuticals, Inc./Athena Neuroscience) and 65234 (Valeant Pharmaceuticals North America) for 0.05 mg and 0.25 mg tablets only. Note: These products are no longer manufactured or available. PERMETHRIN Cream 5 % 60 gm gm PER * PERPHENAZINE * Restricted to: 1) The use of antipsychotics for Medi-Cal beneficiaries less than 18 years of age requires treatment authorization approval; 2) The use of antipsychotics for Medi-Cal beneficiaries residing in nursing facilities is restricted to FDA approved indications. Injection 5 mg/ml 1 ml ml + Tablets 2 mg ea 4 mg ea 8 mg ea 16 mg ea Liquid 16 mg/5 ml ml * PERTUZUMAB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 50242 (Genentech USA, Inc.) only. Injection 420 mg/14 ml ml * PERTUZUMAB, TRASTUZUMAB and HYALURONIDASE-ZZXF * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 50242 (Genentech, Inc.) only. Subcutaneous Injection 600 mg/600 mg/ 20,000 units/ 10 ml ml 1200 mg/600 mg/ 30,000 units/ 15 ml ml * PEXIDARTINIB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 65597 (Daiichi Sankyo, Inc.) only. Capsules 200 mg ea PHENAZOPYRIDINE HCL Tablets 0.1 gm ea 0.2 gm ea Effective April 1, 2019 PHE PHENOBARBITAL Injection 120 130 mg/ml 1 ml ml + Tablets 15 mg ea 16.2 mg ea 30 mg ea 32.4 mg ea 60 mg ea 65 mg ea 97.2 mg ea 100 mg ea Liquid 20 mg/5 ml ml PHENYLEPHRINE Ophthalmic solution 0.12 % 15 ml ml 2.5 % 15 ml ml 10 % 5 ml ml 15 ml ml PHENYTOIN + Tablets, chewable 50 mg ea + Capsules, extended release 30 mg ea 100 mg 1,000s ea 200 mg ea 300 mg ea + Capsules, prompt 100 mg 1,000s ea Suspension 125 mg/5 ml ml 30 mg/5 ml ml PHENYTOIN WITH PHENOBARBITAL + Tablets or capsules 100 mg/15 mg ea 100 mg/30 mg ea Note: These products are no longer manufactured or available. PHY PHYTONADIONE Injection 10 mg/ml 1 ml ml 2.5 ml ml 5 ml ml Tablets 5 mg ea PILOCARPINE Ophthalmic gel 4 % 3.5 gm gm 5 gm gm Ophthalmic solution % 15 ml ml % 15 ml ml 30 ml ml Ophthalmic solution 1 % 15 ml ml 30 ml ml 2 % 15 ml ml 30 ml ml 3 % 15 ml ml 30 ml ml 4 % 15 ml ml 30 ml ml 5 % 15 ml ml 6 % 15 ml ml 30 ml ml 8 % or 10% ml * Tablets 5 mg ea 7.5 mg ea * Restricted to NDC labeler code 58063 (MGI Pharma) and to claims with dates of service from November 1, 2000, through April 30, 2010, for tablets only. PIL (continued) PILOCARPINE WITH EPINEPHRINE Ophthalmic solution 1 % 10 ml ml 15 ml ml 2 % 10 ml ml 15 ml ml 3 % 10 ml ml 15 ml ml 4 % 10 ml ml 15 ml ml 6 % 10 ml ml 15 ml ml Note: These products are no longer manufactured or available. PINDOLOL + Tablets 5 mg ea 10 mg ea PIOGLITAZONE HCL Tablets 15 mg ea 30 mg ea 45 mg ea PIOGLITAZONE HCL/GLIMEPIRIDE Tablets 30 mg/2 mg ea 30 mg/4 mg ea PIOGLITAZONE HCL/METFORMIN HCL + Tablets 15 mg/500 mg ea 15 mg/850 mg ea PIP PIPERACILLIN SODIUM Powder for injection ea PIPOBROMAN Tablets 10 mg ea 25 mg ea Note: These products are no longer manufactured or available. PIRBUTEROL ACETATE * Aerosol inhaler with adapter 14 gm gm 25.6 gm gm * Restricted to dates of service from March 1, 1994, to January 31, 2007. * PIROXICAM * Restricted to use for arthritis. + Tablets or capsules 10 mg ea 20 mg ea Note: Subject to Step Therapy edits. See Drugs: Contract Drugs List Part 8 Step Therapy for more information. * PITAVASTATIN CALCIUM * Restricted to claims submitted with dates of service from October 1, 2011, through October 31, 2014, only. Tablets 1 mg ea 2 mg ea 4 mg ea PLI PLICAMYCIN Powder for injection 2.5 mg/vial ea Note: This product is no longer manufactured or available. * PNEUMOCOCCAL VACCINE, 13-VALENT, CONJUGATED * Restricted to: 1) Medi-Cal beneficiaries 19 years of age and older. 2) One dose of vaccine per lifetime. 3) Use of this vaccine must be based on the guidelines published by the Centers for Disease Control and Prevention (CDC). Injection 1-dose syringe ml * PNEUMOCOCCAL VACCINE, 23-VALENT, NON-CONJUGATED * Restricted to: 1) Medi-Cal beneficiaries 19 years of age and older. 2) Two doses of vaccine per lifetime. 3) Use of this vaccine must be based on the guidelines published by the Centers for Disease Control and Prevention (CDC). Injection 1-dose vial ml 1-dose syringe ml PODOFILOX Topical solution 0.5 % ml Topical gel 0.5 % gm * POLATUZUMAB VEDOTIN-PIIQ * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 50242 (Genentech, Inc.) only. Injection 140 mg ea POLYESTRADIOL PHOSPHATE Powder for injection 40 mg/vial ea Note: This product is no longer manufactured or available. Effective June 11, 2019 POL POLYETHYLENE GLYCOL 3350 Powder 238 gm gm 510 gm gm 17 gm gm POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES Solution 4000 ml ml POLYMYXIN, BACITRACIN Ophthalmic ointment gm * PONATINIB * Restricted to use in the treatment of cancer only. Tablets 15 mg ea 45 mg ea PORFIMER SODIUM Powder for injection ea POTASSIUM BICARBONATE/CITRIC ACID *+ Tablets, effervescent 10 meq ea 20 meq ea 25 meq ea * Excludes NDC Labeler Codes 00245 (Upsher-Smith Laboratories, Inc.), and 66758 (Parenta Pharmaceuticals, Inc.). Effective June 1, 2020 POT POTASSIUM CHLORIDE + Capsules, long acting 8 meq ea 10 meq ea + * Tablets, long acting 8 meq ea 10 meq ea 20 meq ea * Excludes NDC Labeler Codes 00074 (Abbvie Inc), 00245 (Upsher-Smith Laboratories, Inc.), and 66758 (Parenta Pharmaceuticals, Inc.). Injection ml Liquid 10 % ml 20 % ml Note: Payment for oral liquid limited to a minimum dispensing quantity of 480 ml. See California Code of Regulations (CCR), Title 22, Section 51513(b)(5) regarding exceptions. POTASSIUM CITRATE + Tablets, extended release 5 meq ea 10 meq ea POTASSIUM IODIDE SATURATED SOLUTION Liquid ml * PRALATREXATE * Restricted to use in the treatment of cancer and restricted to claims submitted with dates of service from October 28, 2009, through September 30, 2014, only. Injection 20 mg/1 ml ml 40 mg/2 ml ml Effective May 1, 2020 PRA (continued) * PRAMIPEXOLE DIHYDROCHLORIDE * Use in beneficiaries less than 18 years of age requires treatment authorization approval. Tablets 0.125 mg ea 0.25 mg ea 0.5 mg ea 1.0 mg ea 1.5 mg ea * Tablets, extended-release 0.375 mg ea 0.75 mg ea 1.5 mg ea 3.0 mg ea 4.5 mg ea * Restricted to NDC labeler code 00597 (Boehringer Ingelheim Pharmaceuticals) for the extended-release only. * PRAMLINTIDE ACETATE * Restricted to use in the treatment of Type 2 diabetes and labeler code 00310 (AstraZeneca LP) only. 60 Pen injector 1.5ml ml 120 Pen Injector 2.7ml ml * PRASUGREL * Restricted to NDC labeler code 00002 (Eli Lilly and Company) and to claims with dates of service from April 1, 2011, through May 31, 2017, only. Continuing care with a date of service on or after June 1, 2017, is available when the following conditions are met: 1) The beneficiary had a paid fee-for-service claim for this drug on or before May 31, 2017; 2) A claim has been submitted and paid within the past 100 days; and 3) The claim being submitted is within 100 days of the date of service of the last paid claim. Tablets 5 mg ea 10 mg ea PRA (continued) PRAVASTATIN + Tablets 10 mg ea 20 mg ea 40 mg ea 80 mg ea PRAZOSIN HCL + Capsules 1 mg ea 2 mg ea 5 mg ea PREDNICARBATE Cream 0.1 % 15 gm gm 60 gm gm PREDNISOLONE Injection 20 mg/ml 2 ml ml 5 ml ml 10 ml ml 25 mg/ml 10 ml ml 30 ml ml Tablets 5 mg ea Ophthalmic solution 0.12 % 0.125% 5 ml ml 10 ml ml 1.0 % 5 ml ml 10 ml ml 15 ml ml Liquid 5 mg/5ml ml 15 mg/5ml ml PRE PREDNISOLONE, NEOMYCIN, POLYMYXIN B Ophthalmic suspension 5 mg/5 mg/10,000 U/ml 5 ml ml 10 ml ml Note: These products are no longer manufactured or available. PREDNISOLONE SODIUM PHOSPHATE * Oral solution 20.2 mg/5ml ml * Restricted to NDC labeler code 68135 (Biomarin Pharmaceuticals, Inc.) only and to claims with dates of service from April 1, 2005, through September 30, 2008, only. Orally disintegrating tablets 10 mg ea 15 mg ea 30 mg ea PREDNISOLONE WITH SULFACETAMIDE Ophthalmic ointment 0.25 % gm 0.5 % gm Ophthalmic solution 0.2 % 0.25 % 5 ml ml 10 ml ml 15 ml ml 0.5 % 5 ml ml 15 ml ml PREDNISONE Tablets 1 mg ea 2.5 mg ea 5 mg ea 10 mg ea 20 mg ea 50 mg ea PRE PREGABALIN Capsules 25 mg ea 50 mg ea 75 mg ea 100 mg ea 150 mg ea 200 mg ea 225 mg ea 300 mg ea PRIMAQUINE Tablets 26.3 mg ea PRIMIDONE + Tablets 50 mg ea 250 mg ea Liquid 0.25 gm/5ml ml PROBENECID + Tablets 500 mg ea PROBENECID WITH COLCHICINE + Tablets ea PROCAINAMIDE Injection 100 mg/ml 10 ml ml + Capsules or tablets 250 mg ea 375 mg ea 500 mg ea + Capsules or tablets, long-acting 250 mg ea 500 mg ea 750 mg ea 1000 mg ea PROCARBAZINE Capsules 50 mg ea Effective September 1, 2020 PRO PROCHLORPERAZINE Injection 5 mg/ml ml Injection, prefilled syringe ml + Tablets 5 mg ea 10 mg ea 25 mg ea Liquid 5 mg/5 ml ml + Capsules, sustained release 10 mg ea 15 mg ea 30 mg ea Suppositories 2.5 mg ea 5 mg ea 25 mg ea PROCYCLIDINE Tablets 5 mg ea Note: This product is no longer manufactured or available. PROGESTERONE Injection 50 mg/ml 10 ml ml * PROMETHAZINE * Restricted to individuals 2 years of age and older. Injection 25 mg/ml 1 ml ml 10 ml ml 50 mg/ml ml + Tablets 12.5 mg ea 25 mg ea 50 mg ea Liquid 6.25 mg/5ml ml Liquid Fortis 25 mg/5ml ml Suppositories 12.5 mg ea 25 mg ea 50 mg ea PRO (continued) * PROMETHAZINE WITH CODEINE * Restricted to individuals 2 years of age and older. * Restricted to a maximum dispensing quantity of 360 ml and a maximum of three (3) dispensings in any 75-day period. Liquid ml * PROMETHAZINE WITH DEXTROMETHORPHAN * Restricted to individuals 2 years of age and older. Liquid ml * PROMETHAZINE WITH PHENYLEPHRINE * Restricted to individuals 2 years of age and older. Liquid ml * PROMETHAZINE WITH PHENYLEPHRINE AND CODEINE * Restricted to individuals 2 years of age and older. * Restricted to a maximum dispensing quantity of 360 ml and a maximum of three (3) dispensings in any 75-day period. Liquid ml PROPANTHELINE BROMIDE + Tablets 7.5 mg ea 15 mg ea PROPARACAINE HCL Ophthalmic solution 0.5 % 2 ml ml 15 ml ml PRO (continued) PROPRANOLOL Injection 1 mg/ml 1 ml ml + Tablets 10 mg ea 20 mg ea 40 mg ea 60 mg ea 80 mg ea 90 mg ea Liquid 4 mg/ml ml 8 mg/ml ml PROPYLTHIOURACIL + Tablets 50 mg ea * PROTRIPTYLINE HCL * Use in beneficiaries less than 12 years of age requires treatment authorization approval. Tablets 5 mg ea 10 mg ea PYRANTEL PAMOATE Liquid ml PYRAZINAMIDE Tablets or capsules 500 mg ea PYRIDOSTIGMINE + Tablets 60 mg ea + Tablets, long acting 180 mg ea Liquid ml PYRIDOXINE Injection 100 mg/ml 10 ml ml 30 ml ml PYR PYRIMETHAMINE Tablets 25 mg ea * QUETIAPINE FUMARATE * Restricted to: 1) The use of antipsychotics for Medi-Cal beneficiaries less than 18 years of age requires treatment authorization approval; 2) The use of antipsychotics for Medi-Cal beneficiaries residing in nursing facilities is restricted to FDA approved indications. Tablets 25 mg ea 50 mg ea 100 mg ea 200 mg ea 300 mg ea 400 mg ea Extended-release tablets 50 mg ea 150 mg ea 200 mg ea 300 mg ea 400 mg ea * QUINAPRIL HCL * Authorization always required. Tablets 5 mg ea 10 mg ea 20 mg ea 40 mg ea QUINIDINE GLUCONATE Injection 80 mg/ml 10 ml ml + Tablets, long acting 324 mg ea Suspended until further notice. QUI QUINIDINE SULFATE + Tablets 100 mg ea 200 mg 1,000s ea 300-325 mg ea Tablets or capsules ea * Quinine Sulfate * Restricted to claims submitted with dates of service prior to May 1, 2007. Tablets or capsules ea * RABIES VACCINE * Restricted to: 1) Medi-Cal beneficiaries 19 years of age and older. 2) Use of this vaccine must be based on the guidelines published by the Centers for Disease Control and Prevention (CDC). Injection 1-dose vial ea * RALOXIFENE HCL * Restricted to use for the treatment and prevention of osteoporosis and reduction in the risk of invasive breast cancer in postmenopausal women with osteoporosis or postmenopausal women at high risk of invasive breast cancer and to claims submitted with dates of service from October 1, 1998, through June 30, 2009, only. + Tablets 60 mg ea * RALTEGRAVIR * Restricted to use as combination therapy in the treatment of Human Immunodeficiency Virus (HIV) infection. Also restricted to NDC labeler code 00006 (Merck & Company, Inc.) only. Tablets 400 mg ea 600 mg ea Chewable Tablets 25 mg ea 100 mg ea Oral Suspension packets 100 mg ea RAM * RAMELTEON * Restricted to use in the treatment of insomnia and to a maximum dispensing quantity of thirty (30) tablets and a maximum of three (3) dispensings in any seventy-five (75) day period and to claims with dates of service from November 1, 2006, through March 31, 2010, only. Tablets 8 mg ea RAMIPRIL + Capsules 1.25 mg ea 2.5 mg ea 5 mg ea 10 mg ea * RAMUCIRUMAB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00002 (Eli Lilly and Company) only. Injection 100 mg/10 ml ml 500 mg/50 ml ml RANITIDINE HCL + Tablets 150 mg ea 300 mg ea Syrup 15 mg/ml ml * REGORAFENIB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 50419 (Bayer HealthCare Pharmaceuticals) only. Tablets 40 mg ea Effective April 1, 2020 REP * REPAGLINIDE * Restricted to claims submitted with dates of service from April 1, 1999, through July 31, 2005. + Tablets 0.5 mg ea 1.0 mg ea 2.0 mg ea * RIBAVIRIN * Restricted to use as combination therapy in the treatment of Hepatitis C. Also restricted to therapy lasting up to 48 weeks from the dispensing date of the first prescription. Capsules 200 mg ea Tablets 200 mg ea * Dose Pack Tablets (56 tablets per pack) 600 mg Dose Pack (200 mg x 28, 400 mg x 28) ea 800 mg Dose Pack (400 mg x 56) ea 1000 mg Dose Pack (400 mg x 28, 600 mg x 28) ea 1200 mg Dose Pack (600 mg x 56) ea * Restricted to brand name Ribasphere RibaPak labeler code 66435 (Kadmon Pharmaceuticals, LLC) for Dose Pack (tablets) only. Also restricted to claims with dates of service from July 1, 2012, through June 30, 2015. Continuing care with a date of service on or after July 1, 2015, is available when the following conditions are met: 1) The beneficiary had a paid fee-for-service claim for this drug on or before June 30, 2015; 2) A claim has been submitted and paid within the past 100 days; and 3) The claim being submitted is within 100 days of the date of service of the last paid claim. Note: ea means tablet. Bill using outer package NDCs ending in -99 for proper reimbursement. * RIBAVIRIN AND INTERFERON ALFA-2B * Restricted to use in the treatment of Hepatitis C. Also restricted to a maximum quantity of two kits per dispensing, to therapy lasting up to 48 weeks from the dispensing date of the first prescription and to dates of service from July 1, 1999, through June 30, 2005. + Capsules and injection, multi-dose pen ea kit Note: Product is no longer manufactured or available. RIB * RIBOCICLIB * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00078 (Novartis Pharmaceuticals Corporation) only. Tablets 600 mg daily dose (3 x 21 tablet blister packs) ea 400 mg daily dose (3 x 14 tablet blister packs) ea 200 mg daily dose (1 x 21 tablet blister pack) ea Note: ea means number of tablets per box of either 63, 42 or 21. * RIBOCICLIB AND LETROZOLE * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 00078 (Novartis Pharmaceuticals Corporation) only. Tablets 600 mg daily dose (3 x 21 tablet blister packs) ea and 2.5 mg (bottle of 28 tablets) 400 mg daily dose (3 x 14 tablet blister packs) ea and 2.5 mg (bottle of 28 tablets) 200 mg daily dose (1 x 21 tablet blister pack) ea and 2.5 mg (bottle of 28 tablets) Note: ea means total number of tablets carton of either 91, 70 or 49. * RIFABUTIN * Restricted to use in the prevention of disseminated Mycobacterium Avium Complex (MAC) disease in patients with advanced HIV infection. Capsules 150 mg ea RIF RIFAMPIN Capsules 150 mg ea 300 mg ea RIFAMPIN AND ISONIAZID Capsules 300 mg/150 mg ea RIFAMPIN, ISONIAZID AND PYRAZINAMIDE Tablets 120 mg/50 mg/300 mg ea RIFAPENTINE Tablets 150 mg ea * RILPIVIRINE * Restricted to use as combination therapy in the treatment of Human Immunodeficiency Virus (HIV) infection only. Also restricted to NDC labeler code 59676 (Janssen Products, LP.) only. Tablets 25 mg ea * RILUZOLE * Restricted to use in the treatment of amyotrophic lateral sclerosis. Tablets 50 mg ea * RIMEGEPANT * Requires Treatment Authorization Request (TAR) Restricted to 1) Use in patients who have failed or are unable to tolerate a drug in the triptan class of medication; 2) Acute treatment of migraine headache; 3) Maximum fill quantity of 8 tablets per dispensing and one dispensing in 30 days. Also restricted to NDC labeler code 72618 (Biohaven Pharmaceuticals, Inc.) only. Tablets, orally disintegrating 75 mg ea Effective August 1, 2020 RIM * RIMEXOLONE * Restricted to NDC labeler code 00065 (Alcon Laboratories Inc.) only and to claims submitted with dates of service through September 29, 2018, only. Ophthalmic suspension 1 % ml RISEDRONATE SODIUM Tablets 5 mg ea 30 mg ea 35 mg ea * 150 mg ea * Restricted to claims with dates of service from January 1, 2009, through April 30, 2012, for the 150 mg tablets only. * RISPERIDONE * Restricted to: 1) The use of antipsychotics for Medi-Cal beneficiaries less than 18 years of age requires treatment authorization approval; 2) The use of antipsychotics for Medi-Cal beneficiaries residing in nursing facilities is restricted to FDA approved indications. Tablets 0.25 mg ea 0.5 mg ea 1 mg ea 2 mg ea 3 mg ea 4 mg ea Solution 1 mg/ml ml * RITONAVIR * Restricted to use as combination therapy in the treatment of Human Immunodeficiency Virus (HIV) infection. Also restricted to NDC labeler code 00074 (AbbVie Inc.) only. Capsules 100 mg ea Tablets 100 mg ea Solution 80 mg/ml ml Oral powder packets 100 mg ea RIT * RITUXIMAB * Restricted to use in the treatment of cancer. Also restricted to NDC labeler code 50242 (Genentech, Inc.) only. Injection 10 mg/ml ml * RITUXIMAB AND HYALURONIDASE HUMAN * Restricted to use in the treatment of cancer only. Also restricted to NDC labeler code 50242 (Genentech, Inc.) only. Injection 1400 mg/23400 units/11.7 ml ml 1600 mg/26800 units/13.4 ml ml * RIVAROXABAN * Restricted to NDC labeler code 50458 (Janssen Pharmaceuticals, Inc.) only. Tablets 10 mg ea 15 mg ea 20 mg ea Starter Pack Tablets 15 mg-20mg Tablets from 51-tablet Pack ea * RIVASTIGMINE * Restricted to treatment of dementia of the Alzheimers type and to treatment of mild to moderate dementia associated with Parkinsons disease. Use in beneficiaries less than 18 years of age requires treatment authorization approval. Transdermal system 4.6 mg/24 hr ea 9.5 mg/24 hr ea 13.3 mg/24 hr ea RIV * RIVASTIGMINE TARTRATE * Restricted to treatment of mild to moderate dementia of the Alzheimers type and to treatment of mild to moderate dementia associated with Parkinsons disease. Use in beneficiaries less than 18 years of age requires treatment 14authorization approval. Capsules 1.5 mg ea 3.0 mg ea 4.5 mg ea 6.0 mg ea * Solution, oral 2 mg/ml ml * Restricted to claims with dates of service from November 1, 2002, through June 30, 2014, for the oral solution only. * RIZATRIPTAN * Restricted to a maximum quantity per dispensing of nine (9) tablets. Tablets 5 mg ea 10 mg ea Tablets, orally disintegrating 5 mg ea 10 mg ea Effective August 1, 2020 ROP * ROPINIROLE HCL * Use in beneficiaries less than 18 years of age requires treatment authorization approval. Tablets 0.25 mg ea 0.5 mg ea 1 mg ea 2 mg ea 3 mg ea 4 mg ea 5 mg ea * Tablets, extended-release 2 mg ea 4 mg ea 6 mg ea 8 mg ea 12 mg ea * Restricted to NDC labeler code 00007 (GlaxoSmithKline) and to claims with dates of service from January 1, 2009, through June 30, 2012, for extended-release tablets only. Continuing care with a date of service on or after June 30, 2012, is available when the following conditions are met: 1) The beneficiary had a paid fee-for-service claim for this drug on or before June 30, 2012; 2) A claim had been submitted and paid within the past 100 days; 3) The claim being submitted is within 100 days of the date of service of the last paid claim. * ROSIGLITAZONE MALEATE * Restricted to NDC labeler code 00029 (GlaxoSmithKline) and to claims with dates of service through November 18, 2011, only. + Tablets 2 mg ea 4 mg ea 8 mg ea ROS * ROSIGLITAZONE MALEATE/GLIMEPIRIDE * Restricted to NDC labeler code 00007 (GlaxoSmithKline) only. + Tablets 4 mg/1 mg ea 4 mg/2 mg ea 4 mg/4 mg ea 8 mg/2 mg ea 8 mg/4 mg ea Note: These products are no longer manufactured or available. * ROSIGLITAZONE MALEATE/METFORMIN HCL * Restricted to NDC labeler code 00007 (GlaxoSmithKline) and to claims with dates of service through November 18, 2011, only. + Tablets 1 mg/500 mg ea 2 mg/500 mg ea 4 mg/500 mg ea 2 mg/1000 mg ea 4 mg/1000 mg ea ROSUVASTATIN CALCIUM Tablets 5 mg ea 10 mg ea 20 mg ea 40 mg ea     drugs cdl p1c  PAGE 2 Drugs: Contract Drugs List Part 1 drugs cdl p1c Prescription Drugs (N through R)  PAGE 1  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding prior authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Prior authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy ___ Prescription Drugs (N through R) _________ 2003 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 892 Prescription Drugs (N through R) March 2017 drugs cdl p1c  PAGE 2 drugs cdl p1c  PAGE 3 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 946 Prescription Drugs (N through R) June 2019  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding prior authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Prior authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 592 Prescription Drugs (N through R) October 2004 drugs cdl p1c  PAGE 4 drugs cdl p1c  PAGE 3  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 688 Prescription Drugs (N through R) September 2008 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 888 Prescription Drugs (N through R) January 2017 drugs cdl p1c  PAGE 4 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 958 Prescription Drugs (N through R) December 2019 drugs cdl p1c  PAGE 6 drugs cdl p1c  PAGE 5 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 970 Prescription Drugs (N through R) June 2020 drugs cdl p1c  PAGE 6 drugs cdl p1c  PAGE 7 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 970 Prescription Drugs (N through R) June 2020 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 778 Prescription Drugs (N through R) June 2012 drugs cdl p1c  PAGE 7 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 970 Prescription Drugs (N through R) June 2020 drugs cdl p1c  PAGE 8 drugs cdl p1c  PAGE 9 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 970 Prescription Drugs (N through R) June 2020  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding prior authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Prior authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy ___ Prescription Drugs (N through R) _________ 2003 drugs cdl p1c  PAGE 10 drugs cdl p1c  PAGE 9  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy ___ Prescription Drugs (N through R) ___ 2009 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 970 Prescription Drugs (N through R) June 2020 drugs cdl p1c  PAGE 10 drugs cdl p1c  PAGE 11 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding prior authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Prior authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy ___ Prescription Drugs (N through R) _________ 2003 drugs cdl p1c  PAGE 12 drugs cdl p1c  PAGE 11 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 12 drugs cdl p1c  PAGE 13 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 718 Prescription Drugs (N through R) December 2009 drugs cdl p1c  PAGE 13 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 14 drugs cdl p1c  PAGE 15 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 696 Prescription Drugs (N through R) January 2009 drugs cdl p1c  PAGE 15 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 948 Prescription Drugs (N through R) July 2019 drugs cdl p1c  PAGE 16 drugs cdl p1c  PAGE 17 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding prior authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Prior authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 18 drugs cdl p1c  PAGE 17 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 752 Prescription Drugs (N through R) May 2011 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 942 Prescription Drugs (N through R) April 2019 drugs cdl p1c  PAGE 18 drugs cdl p1c  PAGE 19 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 20 drugs cdl p1c  PAGE 19  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 732 Prescription Drugs (N through R) July 2010 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 972 Prescription Drugs (N through R) July 2020 drugs cdl p1c  PAGE 20 drugs cdl p1c  PAGE 21 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 22 drugs cdl p1c  PAGE 21  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 736 Prescription Drugs (N through R) September 2010 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 22 drugs cdl p1c  PAGE 23 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 24 drugs cdl p1c  PAGE 23  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 672 Prescription Drugs (N through R) January 2008 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 24 drugs cdl p1c  PAGE 25 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 26 drugs cdl p1c  PAGE 25  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 732 Prescription Drugs (N through R) July 2010 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 26 drugs cdl p1c  PAGE 27 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 27 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 28 drugs cdl p1c  PAGE 29 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 30 drugs cdl p1c  PAGE 29  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding prior authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Prior authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 607 Prescription Drugs (N through R) May 2005 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 974 Prescription Drugs (N through R) August 2020 drugs cdl p1c  PAGE 30 drugs cdl p1c  PAGE 31  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 956 Prescription Drugs (N through R) November 2019  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 32 drugs cdl p1c  PAGE 31  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 684 Prescription Drugs (N through R) July 2008 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 956 Prescription Drugs (N through R) November 2019 drugs cdl p1c  PAGE 32 drugs cdl p1c  PAGE 33 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 34 drugs cdl p1c  PAGE 33  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 736 Prescription Drugs (N through R) September 2010 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 34 drugs cdl p1c  PAGE 35 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 950 Prescription Drugs (N through R) August 2019  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 36 drugs cdl p1c  PAGE 35  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 686 Prescription Drugs (N through R) August 2008 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 970 Prescription Drugs (N through R) June 2020 drugs cdl p1c  PAGE 36 drugs cdl p1c  PAGE 37 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 967 Prescription Drugs (N through R) May 2020  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 38 drugs cdl p1c  PAGE 37  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 724 Prescription Drugs (N through R) March 2010 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 967 Prescription Drugs (N through R) May 2020 drugs cdl p1c  PAGE 38 drugs cdl p1c  PAGE 39 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 967 Prescription Drugs (N through R) May 2020 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 778 Prescription Drugs (N through R) June 2012 drugs cdl p1c  PAGE 40 drugs cdl p1c  PAGE 39  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy ___ Prescription Drugs (N through R) ___ 2011 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 974 Prescription Drugs (N through R) August 2020 drugs cdl p1c  PAGE 40 drugs cdl p1c  PAGE 41 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 974 Prescription Drugs (N through R) August 2020  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 764 Prescription Drugs (N through R) December 2011 drugs cdl p1c  PAGE 41  * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 766 Prescription Drugs (N through R) December 2011 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 974 Prescription Drugs (N through R) August 2020 drugs cdl p1c  PAGE 42 drugs cdl p1c  PAGE 43 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 974 Prescription Drugs (N through R) August 2020 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 782 Prescription Drugs (N through R) August 2012 drugs cdl p1c  PAGE 43 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 766 Prescription Drugs (N through R) December 2011 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 974 Prescription Drugs (N through R) August 2020 drugs cdl p1c  PAGE 44 drugs cdl p1c  PAGE 45 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 974 Prescription Drugs (N through R) August 2020 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 782 Prescription Drugs (N through R) August 2012 drugs cdl p1c  PAGE 45 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 934 Prescription Drugs (N through R) December 2018 drugs cdl p1c  PAGE 46 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 963 Prescription Drugs (N through R) March 2020 drugs cdl p1c  PAGE 42 drugs cdl p1c  PAGE 47 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 898 Prescription Drugs (N through R) June 2017 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 963 Prescription Drugs (N through R) March 2020 drugs cdl p1c  PAGE 48 drugs cdl p1c  PAGE 48 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 963 Prescription Drugs (N through R) March 2020 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 922 Prescription Drugs (N through R) June 2018 drugs cdl p1c  PAGE 49 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 972 Prescription Drugs (N through R) July 2020 drugs cdl p1c  PAGE 50 drugs cdl p1c  PAGE 51 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 972 Prescription Drugs (N through R) July 2020 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 922 Prescription Drugs (N through R) June 2018 drugs cdl p1c  PAGE 52 drugs cdl p1c  PAGE 51 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 922 Prescription Drugs (N through R) June 2018 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 972 Prescription Drugs (N through R) July 2020 drugs cdl p1c  PAGE 52 drugs cdl p1c  PAGE 53 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 972 Prescription Drugs (N through R) July 2020 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 972 Prescription Drugs (N through R) July 2020 drugs cdl p1c  PAGE 53 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See paragraph (7) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. 2 Drugs: Contract Drugs List Part 1 Pharmacy 972 Prescription Drugs (N through R) July 2020 drugs cdl p1c 54 * Code I. See paragraph (2) of General Provisions in the Drugs: Contract Drugs List Introduction section of this manual regarding authorization and prescription documentation requirements. + Frequency of billing requirement. See paragraph (3) of General Provisions in the Drugs: Contract Drugs List Introduction section regarding information and exceptions. Cost is based on this package size. See paragraph (4) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Authorization not needed for continuing care. See paragraph (6) of General Provisions in the Drugs: Contract Drugs List Introduction section for more information. Drug is exempt from the monthly drug claim line limit. See ^df   O f g q   F G a b x y z { ڵگگگگگ h>^J hH^Jh^hH5^J hRhHh^hH\h^hH6]^Jh^hH^Jh^hH5\hHh^hH6 h^hHBf g q ss !8P$gdH 88P$8]^8`gdH 8$gdH !P gdH XP gdH !XP gdH XP ]gdH  y z  !@8 $gd> 8 $gdH 8P$h^h`gdH 8Ph]^h`gdR 8P$gdH 8$gdH     # $ ' 1 2 5 : ; = > A B I J M U V W Z  W xxh&hW\ h&hWhWhhW\h^hW5\h~mhH5\^Jh^hH5\^JhOhH\^JheBhH5heBhH5>* hH5>*h5W hHaJhHh^hH^J hH^J h^hHh>/    ' 5 A B s !! 8`$]gdH !8$8]^8`gdH !X@ gdH !8 $gdH  ! $gdH 8 $gdH  8 $gd> X Y o | } t 8 $gdW !8$]^`gdW 8$]^`gdW !8$^`gdWgdW 8P$gdwO 8P$gdH W X Y Z o | } } ~  Z[\]^_rsŽ}hchW\ hW\hIhW\h&hW7\^JhPwHhW5\h&hW7\h."ahW57\h."ahW\ hchWhWhihW6 hihW h&hW h^hWh|@hW5h&hW\^J1 ]^rs 8P$gdW 8 $gdW !8$^`gdW 88P$gdWgdW 8$B@BgdW 8$B@BgdW />VW\'=LMOP\ϺϺtfth&8>h5CJ\aJhZ& hCJ\aJh h^hhH+hH+h5hH+hH+5 hH"5\hhh#\^JhhW\^JhW5\^Jh^>hW5\^Jh^hW5\^JhWh^hW5\hchW\h^hW>* h^hW' />VWoo 88P$8]^8`gdW !8$gdW !8$gdW !8$gdW 8$gdW XP gdW !8P$gdW kY 8$gd !! 8#$gd 8#$gdgd XP gd: !! 8`$]gdh# !! 8`$]gdW 88P$8]^8`gdW '=LM] XP gd 8$gd !8$ ^` gdgd !8$gd !8$gd\]^_`@YZ\ʾ񰰨񰗰񰰰h^hB*^JphhPnh\h^h^Jh^h5 h^h hhh`kh5\^J h`kh h5>*h$h5>* hZ& hh&8>h5hhZ& hCJaJ6@\]t 8$]^`gd]gd XP gd !8$gd 8$gd  $gd\]t  !"#(]^_hijkü hK 5>*hAhK 5 hK \hU ghK 5^J hK ^JhK hK 5h)| hPnhh#h5\^Jh^h5\^Jh,cTh\^Jhh^hCJaJh^h\ h^h5 "#v]gdK  !8$]^`gdK ]gdK  !! 8p$gd)| 8$(gd !! 8`$]gd !8$]gd #^_i34Vo 8$%^`%gdK  8$ (^` gdK  8$]^`gdK  pH!$ ^` gdK gdK ]gdK  !8$8]^8`gdK    %'/03ADHLMT\]k2ͻԦh\hK 5 h\hK hAhK h(hK hK 5>*hhK 5>*hAhK 5 hhK hK hhK 5^J hK \hAhK 5>*\ hK 5^J h(hK 82346PSUVWXYopqr   ĺhg;` hg;`5hhg;`5hH" hh^hhxkhK 5^J hK 5^JhK hAhK h(hK \h(hK ^J h(hK h\hK h\hK 5^J?@ABOPbdgij34=BCDYZ hg;`5hhg;`CJaJ hg;`\h7hg;`\^J hg;`5^J hg;`5\h7hg;`5\h7hg;`57\hg;` hg;`^JGBPj4CDZ 8$gdg;` 8$]^`gdg;`  ]gdg;`]gdg;`]^`gdg;` !8$]^`gdg;` !"#-/34789;<=>@ABC[\]^    !*,34 hg;`\ hg;`^Jh~hg;`5h.bhs hg;`5^Jhg;` hg;`5 hg;`\^JP !"#<=> 8$]gd } 8$]gds]gdg;` 8$]gdg;` 8$gdg;` !8$8]^8`gdg;`>BC\ 45st !8$8]^8`gdg;` !8$]gdg;` !8$]^`gdg;` 8$]gdg;` 8$]^`gdg;`]gdg;` 45:rst  #%IJTUjkowxz#%mnop hg;`\^J hg;`\ hg;`^J h^hg;` hQhg;`hQhg;`5h~hg;`5hg;` hg;`5 hg;`>*Lst IJ} !8$8]^8`gdg;`  !]gdg;` 8$]^`gdg;` 8$]gdg;` !8$]^`gdg;`]gdg;` JUkxnoyyyy 8$]^`gdg;`]gdg;` !8$]gdg;` !t 8$]^`gdg;` !8$]^`gdg;`  ]gdg;` xy 8$]^`gdg;`  ]gdg;` !8$]gdHm$ 8$]gdg;` *,wxy #%8 h^hg;` hg;`5^J hg;`^J hs+hg;` hg;`5\ hg;`\hg;` hg;`5h6ghg;`5h.bh0pL+?Mb 8$]gdg;` 8$]^`gdg;` !8$]^`gdg;`#%+?Mbcdefhij       $ * , 6 ; ? @ B C N O !!!!!!!!!!!!!üѵ hQhg;` h-$xhg;` h`8hg;` hVhg;` hwhg;` hjhg;`h^hg;`^J hg;`5hQhg;`5 hchchg;` h^hg;`CbcdeijvZ 8$]^`gdg;`# XP 8$d]^`gdg;` 8$]gdg;` !8$]gdg;`gdc !! 8`$]gdc !! 8`$]gdg;`  $ ? @ N !!!?!"" !8$]^gdg;` !8$]gdg;` 8$]^`gdg;` !8$]^`gdg;`!!#!>!?!!!!!"""" "#"9"X"""""""""""""""###### ###########򺺲򛑑򧍉yyhg;`^JaJhQhg;`5hchH"h^hg;`5\ hg;`\ h!hg;`hg;` h\_hg;`h\_hg;`5 hz\hg;` haihg;`haihg;`>*\hQhg;`6\ hQhg;`hQhg;`\ h12fhg;` h^hg;` hwhg;`.""#########%%&%]^`gdg;` 8$]gdg;` XpP gdg;` 88]^8`gdg;` 8]gdg;` 8$]^`gdg;` ############$$$$$'$($*$$$$$%%%%%$%%%&%*%X%}%~%%%%%%&&&&&$&%&&&(&)&ѷ㬤㜜㔉h-$xhg;`^Jh-$xhg;`^JaJhg;`^JaJh^hg;`6h^hg;`5h5yhg;`^JaJhaihg;`^JaJhh9hg;`6 h-$xhg;` hh9hg;` hkBhg;`hg;` h^hg;` hg;`\hkBhg;`\h^hg;`\2&%X%}%~%%&&&V&'''7(f! ! 8$]^`gdg;` 8$]^`gdg;`]^`gdg;` 88]^8`gdg;` 8$]gdg;` !8$]^`gdg;` )&*&U&V&X&&&&&&&''''I'h'''''''''''''''''''''((((7(8(9((((((((((󴫴h^hg;`6]^Jhg;`6]^J h!hg;`h!hg;`^JhUhg;`^JhUhg;`^JaJh^hg;`^Jh^hg;`7haihg;`^Jhh9hg;`6 hh9hg;` h-$xhg;`hg;` h^hg;` hg;`^J47(((((-)m))))nn !8$]^`gdg;` !8$]^`gdg;` !8$]^`gdg;` 8$]gdg;`! !8$]^`gdg;` ((((((((((((())))))-)5)K)m))))))))))))))))****=*[**************併䧧䧧h;0 h.b5hRgh>* hhohg;`h^hg;`6]h^hg;`5h^hg;`5\ hg;`^Jh^hg;`]^JaJh^hg;`^JaJ h^hg;`h^hg;`6]^Jh^hg;`^J8))))*******p XP gdH^0 XpP gdg;` !88]^8`gdg;` !8$]gdg;` !8$]^`gdg;` 8$]^`gdg;` *****s,t,,, -0-b-----]gd.b 8($gd.b !8($gd.b]^`gd.b XpP gd.b 8$]gd.b XP 8$gd*********+ +/+6+++++, , ,r,s,t,,,,,,- - -0-b----------. .&.'.(.O.n.........../ ///8/;/ϲhzh.b5 hI4@h.b hzh.b hZ& h.bh{h.b5 hh.b h^h.bhaih.b^Jhh9h.b6 h-$xh.b hh9h.bh.b haih.b@-'.(.O.n......//S/i/////////////////0 000/00010G0^0_00000000000000001 111 1h1ƿѸƿƿƿƿƛh^h 5 ht{h h\_h 5h+`h 5 hKf h h&Kh hzh h9h h^h h haih hr:h 5hc5>*\h;]h.b\ hS*\h.b h^h.b hh.b4////////0/0G0_0000001 XpP 8]^8`gd  !8$gd  8$gd  XpP gd  8$gd V11111^3_3333e4f4d XpP 8]^8`gd  !  $gd  !8$gd ]^`gd  XpP ]gd  XP 8]^8`gd  XpP gd h11111111111112 22!2A2a2222223 3]3^3_333333334 4 4(4e4f4r4444444444ϼﵭ咽֋ h;]h h V h,3_h h;_h 5hWh 5 h h h^h 5 h)vh hh ^JaJhh9h 6 hh9h h h-$xh hMTh hEWh h^h h^h 6]3f4r444444444 56v 8$]^`gd  !8$]gdIG !8$8]^8`gd  XP gd  !8$gd  XpP gd 44444444445 5 5 5 5A5H5h5555556 66666666666667 77H7q777777777778 8 8 88ȹڪϢϓhDh 5 hk2h h^#h 5h^h 5 hh h8h hh9h 6 hh9h h h-$xh h^h h h hr:h hr:h 5h Vhc58666667H7q777777 8 8 XpP ]gd  !8$gd  8$gd  XpP gd " !! 8`$]^`gd 8X8v8|8}8888888888889 9 99T9U999999: :2:Q:R:S::::::::; ;;;;;];{;;;;;;;;;ǿܷhr:h 5\h \mH sH hc\mH sH  h`xh hDh 5h8h 6 h8h h\_h h-$xh h^h h h jh ]h jh 6] h jh 7 8888R:S::::;;;;;tt XpP X^X`gd V 8$gd  !8$gd  8$]^`gd  XpP gd  8$8]^8`gd ;;;;;;<<<O<[<g<s<<<<< !8$gd  !8$gd  XpP ^`gd  XpP gd  8$gd  XpP X^X`gd V;;;;;;;;;;;< <;<<<O<[<g<s<<<<<<<<<<<<<<<<<<<<<<<<===== =#=1=F=G=M=N=P=Q=S=d=e=k=l=n=o=q======================h^h \h1uh 5 h^h h hz{h hr:h \T<<<=#=1=S=q=======d>e> XpP gd  XpP ^`gd  !XpP gd  8$gd  8$gd ==========> > >">c>d>e>}>~>>>>>>>>>>>>? ?4?5?6?E?F?N?O?Q?S?T?W?d?h?j?k?l?m?n?r?s?}?~??ûôh^h-[5 h^h-[h-[h*Unh-[5h@yo hXg^J h 5 hv!h h1uh 5 h\h hS.h hd_Zh \ hIh hk2h h~ h h1uh h^h h 6e>}>~>>5?6?T?k?l?m?n?va !X8$gd@yo XpP X^X`gdXg !8$]gdXg 8@$gd  !XpP ]^`gd  !XpP gd  8$`gd n?r?s?}??????@H@I@r !8$]gd-[ XpP gd-[ !8$gd-[ !! 8`$gd-[ !8$gd-[ 8$gd-[ !XpP gd-[ ???????????????????@ @G@H@I@J@V@W@X@Y@@@@@@@@@@@@A AGAfAgAhAiAjAxAyA~h&hU5 h8Chch-[h@yo h5!h-[h5!h-[\h\h-[\h~Wh-[\h(Vh-[\ h(Vh-[ h-[\h^h-[\^Jh^h-[\ h^h-[h&*hl|hU5>*h(hU5h(hU5\h&hU\ h&hU h^hU hshUh=HhU\hU hU^Jh\/hU^Jh!hU5\^Jh\/hU\^J(E FF,FFFFFFFFFF !8$gd8o !8$gdU 8$]^`gdU 8$]gdU 8$gdU !8$]^`gdU FFFFFFFFFFFFFFFFG G GG9G|GHHIIJJJ J!J&JuJvJKuKvKKKKKKKKKKĹĥ͛ěđwhRAh \^JhRAh ^J h \^Jhh \^Jh\/h 5^Jhi5h 6^Jhi5h \^Jhi5h PJ^Jhi5h ^J h ^Jh*Unh 5^J h +ihchc hU5hUhl|hU5 hUhU-FFF GII J!JKKKKK8N9N| !88$]gd  !88$]^gd  88$8]^8`gd  !8$]^`gd  !8$]gd KKLLLLN N7N8N9NuNvN}N~NNNNNO OuOvOOOOOP PPPPPPPP%P&P'P(P)P7P8PBPCPEPݽ}sh*\^Jha/h*\^J hQ?Q@QKQLQjQuQvQwQQQQh$M\h*\ h$M\h*\^Jh*\^J hRCRuRvRyRzRRRRRRRRRRRRRRRRRRSSSSSS S S SSOSQSuSvSSSSSSSS׻h.5sh/0\h5h/0\h-xh/0\h #Th/0\ h/0\hph/05\hv:h>* h.5sh{hRyRzRRRRRRc" !! $&]^`gd*\^JhAhcX457^JhcX4 hcX4\^J huShcX4huShcX4^JhAhcX4^J hcX4^J hcX45^Jhh{BVVVVVVV,W-WMWNWbW XP 8$]`gdcX4 8$]^`gdcX4 8$]gdcX4 & X8pP $gd !8$]gd{ bWvWWWWtXuXX1Y2Y[Yxx\ 8$ ]^` gdcX4 8$]gdcX4 !8$]^`gdcX4 8$]^`gdcX4 8$]^`gdcX4 !8$]^`gdcX4 /Y0Y1Y2Y3Y;YFYGYTYYYZY[YoYpYrYtYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY˿˿hcX4huShcX47huShcX47\hAhcX45\^JhAhcX457\huShcX457\huShcX45\^JhuShcX45>*\^JhAhcX457^JhAhcX45^J hcX4^Jh= hcX45\^J5[YpYYYYYYYYYYYYYYYYYYYY P!gdcX4 XpP 8]^8`gdcX4 8$]^`gdcX4YYYYYYZZZZ Z Z Z ZZZ+Z,ZGZKZTZXZeZfZZZZZZZZ[[[,[9[F[G[S[T[`[a[[[[[\A\C\D\G\T\y\z\{\\\h^hY$T\^Jh 3hY$T^J hhY$ThY$T h-xhY$T h^hY$T hY$T^JhcGhY$T5^J h5 hi~h"hK)^hcX4^JhcX45\^Jh= hcX45\^J hi~hcX4hcX48Y Z Z ZZZ+ZKZXZeZ[wwwY !8$]^`gdY$T 8$]^`gdY$T 8$ ]^` gdY$T 8$]gdY$T P!gd P!gd" 8$ ]^` gdcX4 [[,[9[F[S[a[z\{\\\\\\W]X]] ^ 8$]^`gdY$T !8$]^`gdY$T 8$]gdY$T\\\\\\\\]G]T]V]W]X]Y]Z]]]]^ ^ ^4^G^T^U^V^Z^[^^^^^^^^^^^^^^_____#_$_6_7_9_:_G_H_T_y_____¸﨡 h>EhY$T hC?[hY$T h.5shY$Th^hY$T^JhcGhY$T5^Jhch h hY$Th%hY$T5h hY$T5 h%hY$T hAhY$T hY$T^J h^hY$ThY$T< ^ ^4^U^V^^^^^^^^mmm 8$gd !8$8]^8`gdY$T 8$]gdY$T  X8$`gdY$T  X8$^gdY$T 8$ ]^` gdY$T ^^^^__$_6_7_G__e  X8$]^`gdY$T 8$]gdY$T  X8$gdY$T !8$]gdY$T !8$]^`gdY$T 8$]^`gdY$T _______```````v ! X8$gdY$T  X8$^`gdY$T  X8$gdY$T  X8$gdY$T 8$gdY$T  X8$ ^` gdY$T _______` ```````G`T```````````````aa6aGaHaIaMaNaTa\a^aaaaaaaaaabGb¼¼µɌɼhY$T@^Jh^hY$T@^J h2hY$ThHhY$T^JhphY$T5^Jh h^h{ hY$T^J h^hY$Th^hY$T^JhAhY$T^Jh^hY$TB*^JphhY$TB*^Jph hwnhY$T h.5shY$T4``a6aGaHaIaMaNa\aibbocpctt ]^`gdY$T ]^`gdY$T  gdY$T hpP gd !8$gd{ ! X8$gdY$T  X8$gdY$T GbTbibbbbbbbcGcTcocpc~ccccccccccccccccccdGdTdhdidjdkd}d~dddddddddddddddƿԫԠԙ񒙋 h-$xhY$T hEhY$T h%hY$T h.5shY$Th^hY$T\ hY$T\h5!hY$T^J hY$T^Jh^hY$T^J6pccccccjdkd~dddnXX !8$H^HgdY$T !8#$gdY$T ]^`gdY$T  gdY$T  X8$gdY$T "! X8"$gdY$T X8"$gdY$T !H"$gdY$T dddddddeeedR !8P$gdY$T (l$ ]^` gdY$T ]^`gdY$T !8P$gdY$T  gdY$T !8$H^HgdY$T ! X8$gdY$T  X8$gdY$T ddddddddddddddeeGePeTeoeeeeeeeeeeeeeeeeeefGfTfwfxfzffffffg"g#g$g2g3g4g5g7gGgʿʲh^h{ Q^J h^h{ Qh{ Qhph{ Q5h' h{\hY$T^JaJh^hY$T^JaJ h^hY$Th%hY$T\ h%hY$T hNhY$T h.5shY$ThY$T h-$xhY$T hh{ Qh{ QhNh{ Q^Jh-$xh{ Q^Jhvmh{ Q^Jhhh{ Q^JhkBh{ Q^J hkBh{ Q hhh{ Q h^h{ Q h{ Q^Jh^h{ Q^Jh^h{ Q\^J h{ Q\^Jhph{ Q5\^Jh hNh0kykzkkkkkkkUlVliljlyll !8$gd{ Q !8$]^`gd{ Q !8$gd{ Q 8$gd{ Q 8$ ^` gd{ Q 8$^`gd{ Qlllmmmnn2ooooov XP gd 8$]gd{ !8$^`gd{ Q !8$^gd{ Q !8$]^`gd{ Q 8$gd{ Qgd{ Q llllmGmTmmmmmmmnnGnTn\n]nnnnnnnnno2oGoToooooooooooooop p!p1pGpTppp ho\^Jh^ho\^Jh^ho\\^J ho\\^Jhpho\5\^J h5\h{hoh{ Q^Jhh{ Q\^J h{ Q\^J h=Hh{ QhDvh{ Q^Jh^h{ Q\^Jh^h{ Q^J3oooo p!ppppqqoqpqrrs !8$gdo\gdo\ 8\8]\^8`gdo\ !8$]^`gdo\ !8$^gdo\ 8$gdo\pppppq qqqGqTqmqnqoqpqtquqvqqqqrGrTrrrrrrrss3sGsHsTs^ssstsssssssstGtTtettttttu(uGuTulunuoupuܺ캺캺hpho\\ h'ugho\ho\hho\\ h^ho\hAho\5\h^ho\5\ ho\\^Jh^ho\\^J ho\^Jh^ho\^Jh/ho\\^J>s3sHs^stsssssnuouuuv_v`vavbvfvgv XP gd 8$gd{ 8$^`gdo\gdo\ 8$^`gdo\puquuuuuuuuuuuuuuvvGvTv^v_v`vavbvfvgvivjvyvzvvvvvvvvvvvwwGwHwIwKwLwTwXwYwwwwwwwwxx»ᩢh^ho\\ h^ho\ hHho\ h|ho\ho\ h]ho\ hH}ho\hpho\\hpho\5\ hRgh h{^J hyDho\hyDho\^Jh^ho\^J ho\^J:gvyvvvwHwIwXwwwwxx}}k 8$gdo\ !8$^gdo\ 8$^`gdo\ $^gdo\ H$^gdo\ 8$]^`gdo\ 8$gdo\ xxx)x*x+xGxTxkxlxxxxxxxxxxxxxy&yGyTyyyyyyyyz zzzz%z,z7z8z;zEzFzGzTzYzmznzozpzqzuzvzzzzzzzz{{{{;{hpho\5 hT5\hTP=h{^J h{\^JhP_ho\\ho\ ho\^Jhoho\^Jh^ho\^J h^ho\ hZhho\ hTP=ho\Bx)xxxxxxyy zfP !8$^gdo\" ) X8pP $ ^` gdo\ (! X8pP $gdo\ !8$^`gdo\ 8$gdo\ !8$(^`gdo\ !8$(gdo\ zz%zEzFzYznzozpzqzuzvzz|gd 8$]gd{ !8$^`gdo\ & X8pP $gdo\gdo\ !8$^gdo\ 8$]^`gdo\ zzzz{{{A{\{l{|{}{{{| '!  8pP $gdo\ $!  8pP$gdo\ #  8pP$gdo\ #  8pP $gdo\ 8$]gdo\ $gdo\ ;{A{G{T{\{l{v{|{}{{{{{{{{{{{{{| ||)|A|G|P|T|_|`|n|s|||||||||}>}G}T}|}}}}}}}}}}}~~~~~ ~͹ͳh2hmHsH h)h{h{ ho\@hTP=ho\@H*hTP=ho\@H*hTP=ho\@hTP=ho\@ h)ho\ hTP=ho\h^ho\5ho\ h^ho\<{{{{{{ ||)|A|P|_|`|n||| 8$^gdo\ !8$gdo\ 8$]gdo\ !8$gdo\ XpP gdo\ 8$gdo\|>}}~~~ ~0~1~?~Y~g~v~}kkk 8$gdo\ XpP gdo\  gdo\ !XP gd 8$]gd{ XpP ]^`gdo\ XpP ]^`gdo\ ~#~/~0~1~?~G~T~Y~g~v~~~~~~~~~~~~GT#GT̀ԀՀـڀۀ2345 h^h{ h^Sho\hUho\5h^Sho\5h)ho\\^Jh)ho\\ hvmho\h)ho\5\ h)ho\ h1Kho\ hTP=ho\ho\ ho\5hpho\5;v~~~~~~~~~j 8$]^`gdo\"$ XP 8$]^`gdo\ 8$]gdo\ XpP gdo\ !8$gdo\gdo\ #  8pP $gdo\ #ԀՀ345~~ !8$]gd{ !8$8]^8`gdo\ XP 8$]`gdo\ 8$]^`gdo\ 8$]gdo\ 569:;GIJL56GZ[\qsvwǂȂɂׂ؂56GSTUqrsw݃乮hLh!5^J h!5\hLh!5>*\hLh!5\ h!\h!5\^Jh!B*\^Jph h!\^J h!^Jh! h!5h2h5mHsH>56:;J[\wȂɂ؂TUrs !XP $gd! 8$]^`gd! 8$]gd! XP gd݃ރ !"#$01567:;>BEGL\]^`abcejlmqrxɄׄ ()/23ηhLh!\hLh!\^JhLh!5>*\^J h!^JhLh!5^Jh!hLh!5\hLh!5>*\h!5>*\E"#c56J|| !8$ ]^` gd! !8$ ]^` gd! XpP H]Hgd! 8$]gd! 8$]^`gd! 3456IJ^_lmnopqs}…Åʅ˅ׅ؅+,9:OQRSU`ab»»»»»»»»» h8L\^J h8L^Jh8L5\^Jhh:"hLh!5hLh!5^Jh! h!^JhLh!\^JJJ_mnopqÅ؅yy 8$]^`gd8L 8$]gd8L XP gd]gd:"]gd! 8$]gd! !8$]^`gd!؅,:RSa݆+ 8$]gd8L !8$]^`gd8L 8$]^`gd8Lʆˆ܆݆*+89Uabwy|~ʇˇևׇ*+,-012>?U[\bijuvĽ h8L5>* h8L5h h`h{ hRi%hshfEhs5hRi%hs5hsh8L h8L\^J h8L^JJ+9bׇ*+i !8$]gds !8$8]^8`gds 8$]gds 8$]gd8L 8$]^`gd8L !8$]^`gd8L +,-12?\jv !8$]^`gd8L 8$]^`gd8L 8$]gd8L 8$gd !8$]gd{ʈˈ ,-;<HIUWXbdestʉˉщ҉߉>Ubyz{|}ʊˊ͊ڊ!.=JKOPhfEh1/5hRi%h1/5 hjh1/h1/ h1/5hv!th1/5hh{ h)h1/h8LL -<IXet҉z{| 8$]gd{ !8$]^`gd8L 8$]^`gd8L|}͊ڊ!.=JK !8$]gd1/ !8$]^`gd1/ 8$]^`gd1/ 8$]gd1/ !8$gdPUbqƋʋˋڋ,.8;=>?U^bkqznjȌʌˌՌ56IUbqsʍˍٍ͍̍û೫hfEh1/5hRi%h1/5h$Ch1/\h]h1/5\ hRghh{h)h1/\ h1/\h)h1/@ h)h1/h1/ hRi%h1/CKƋڋ,>}} !8$]^`gd1/ 8$]gd1/ 8$]^`gd1/ !8$]gd1/ !8$8]^8`gd1/>?^znjȌՌ 8$]gd !8$]gd{ 8$]^`gd1/ !8$]^`gd1/ 8$]gd1/56Isٍ͍̍+,8]^8`gd1/ !8$]^`gd1/ 8$]^`gd1/ !8$8]^8`gd1/ 8$]gd1/ٍ+,1PUVbqʎˎ#$%&8DPQRSUWXbeqſ޿Ŷŭޣ~h`h7e5 h)h7eh7eh]h7e5hdY h{^Jh)h1/\^Jhh1/^Jhoh1/^J h1/^Jh8#h1/^Jh1/h)h1/6]^Jh)h1/^Jh)h1/5\hW/h1/\ h)h1/.$%8DPQRSWXe 8$]gd7e !XpP gd !8$]gd{ 8$]^`gd1/ 8$]gd1/ ]^` gd1/ eȏɏߐ28N}} 8$]^`gd7e !8$]gd7e !8$8]^8`gd7e 8$]gd7e !8$]^`gd7eȏɏʏˏ#%Ubqʐːސߐ#1234U^`abqʑˑ78:HKM׽쯯נ h,h7eh)6h7e5 h)h7e hB:h7e hP_h7e hHvh7e h7e5 hh7e h?h7e h)6h7e h K h7eh7e h`h7ehfEh7e5?MNOUYbqvʒ˒%&'()*34:=?@ABCU]bq“Óʓ˓֓ݓޓߓǿ hg;`5hh{hxkh7e5^J h7e5^J h`h7ehfEh7e5h`h7e5h)6h7e5 h7e5hch7e5>* h7e5>*hch7e5h7e h)h7e*\hrhg;`7\ hg;`\hrhg;`\hAGhg;`\hrhg;`>*\ hEhg;` h&x\hg;`h]hg;`\hg;`AZpqg !8$`gdg;` !8$]^`gdg;` !8$]^`gdg;` 8$]^gdg;` 8$]gdg;` 8$]`gdg;`  #&123FGITUVWX_amnopqtwyz{|}~Õɕ  hg;`^Jhg;`CJaJ h&x\hg;`h&x\hg;`\h&x\hg;`CJaJh&x\hg;`CJ\aJhg;`O23Uz uuu !8$]gdg;` ^`gdg;` 8$]^`gdg;`gdg;` 8$]^gdg;` 8$]gdg;` !(%#^#`gdg;` ,-.23Fk 8$]^`gd|^ 8$]gd|^ !XP gd !8$]gd(@ !8$]gdg;`#$&'+,-./123EFGHPU]^_`cfhijklmopsvxyz{|}~ԿԿԿԿԿԫԿ hSWhh|^h|^5>*\h? h|^5hSWhh|^5\hch|^5\h]h|^5>*\h]h|^5\h|^ hfEh|^ h|^5hfEh|^5hh(@hT{shg;`\hg;`:k{GYjvw()}l}8]^8`gd|^ 8$]gd|^ 8$]^gd|^ !8$]^`gd|^ 8$]^`gd|^ 8$]^`gd|^ #$.CDEFGHQUXYZfijklpqrsuvw|̗͗Ηϗߢ h|^6] h|^5 h|^^JhSWhh|^5\^Jhch|^5\^JhSWhh|^5>*\^Jhch|^5\h|^5>*\h? h|^5hSWhh|^5\h]h|^5>*\h|^;ϗ#$'().:;<=>?SUXYZ[^acdefghjknqstuvw̘ҘƼ h|^^JhSWhh|^5\h]h|^5>*\hch|^5\h|^5>*\h]h|^5\h? h|^5hH\Ah|^5\hH\Ah|^5>*\h|^ h|^6]?)=fvw\]w 8$]^gd|^ 8$]^`gd|^ 8$]gd|^#$.45U[\]fvwxʙיۙܙݙޙ#$89:?@MPU_fm{ hD"jh|^h)h|^5^J hI?h|^ h!VAh|^hfEh|^5h h)h{ h|^5h? h|^5 h)h|^h|^Hܙ89P_m{š 8$]^`gd|^ 8P!$gd 8$]gd{ !8$]gd|^ 8$]gd|^šʚКךޚ#$?@MUYZ[fqʛכ؛ #$?@MUfʜל#$?@FGMUfʝם#$) hfEh|^ h(h|^ hI?h|^ h?h|^h|^ hD"jh|^ h)h|^RšКޚZ[qכ؛*+ !8$]gd|^ H8$]^`gd|^ 8$]gd|^  ^`gd|^ 8$]^`gd|^)*+>?@JKLMNOU\]^_fjkz{ʞ֞מ"#$>?@JMNUWfkxş찤h)h|^5OJQJh)h|^\h)h|^5\hh|^\ h|^^J h|^5^Jh]h|^5^J hRghh{ h)h|^h|^h(h|^>*@+>KLMN^_ky  gd|^ 8$]^`gd|^ !8$]gd|^ Xp gd !8$]gd{ !8$]^`gd|^ʞ֞">JWkxş՟ 8$]gd|^ !8$]gd|^ 8$]^`gd|^ !8$]^`gd|^şʟ՟ן#$?@BMUfwàĠʠנ #$?@MU½h)h!^J h!^J hLh!hfEh!5hLh!5 h!\ h)h!h! h!5h]h!5hRghcmHsHhcmHsHh }mHsHh|^ h)h|^;՟Bw !8$]^`gd! 8$]^`gd! 8$]gd! XP gd } !8$]^`gd|^ àĠա~j~~~jj 8$]gd! 8$]^`gd! !8$]^`gd! !8$]gd! !8$8]^8`gd! h8$gd! Ufʡաס #$1>?@MUfjwʢ΢עڢ ĺhVh!5h Hh!5\h Hh!5>*\ h!5hh{ h)h!h!h-h!\^J h!^Jh)h!^JF1>jw΢ڢ 8P$&(gd 8$]gd{ 8$]gd! 8$]^`gd! -<K[k{ʣߣ()DU 8$]^`gd! 8$]gd! "#%(*+,-/124679:;<>?@ACFHIJKMNOPQSUVXYZ[]_`abcefhijkmopqsvxyz{}h!hVh!5h Hh!5\ h)h!h Hh!5>*\Sʣңӣߣ ()DUV]cjtz~ҤӤ )=>?@ABLU]^_`cdev hAh!h]h!5h5>*^JaJh{ h!5hVh!5h!\^JaJh! h)h! hm~h!IUVc )>?@^_ !8$]gd{gd! 8$]^`gd! !8$]^`gd! 8$]gd!_`devǥԥ!.;Vb !8$]^`gd! 8$]^`gd! 8$]gd! !8$]gd! XP 8$gdv|ǥԥܥݥ!.;Vbcnop|}̦ͦզ֦ڦ 깱hoh!\hZhh!\ h2fh! hSWhh! hDh!h8h!5hDh!5h! h)h!hAh!5 hAh!Bbop}̦ͦڦ=>Z} !8$]^`gd! !8$]gd! !8$8]^8`gd! 8$]gd! 8$]^`gd! =>PZgikvwէ֧ާߧ()*+EFcz{|}~Ө&'(+žžž hAh!hAh!\h!h]h!5h8&5>*^JaJhXg h)h!h2fh!\h)h!\KZgwߧ() 8$]gd! XP 8$gd8& 8$]gdXg !8$]^`gd! 8$]^`gd!)E{&\]lmũƩթ֩: !8$]^`gd! 8$]^`gd! 8$]gd!+\]cklmo|ũƩԩթ֩ةީߩ9:;<P\ivժ֪ުߪ .;<=黶 hc5 h \5h^h!\ h!\h8h!\h)h!\hZhh!\h! h)h! hAh!hAh!\E֪ .;<=>NO[v 8$]gd! XpP gd# !8$]gd! 8$H]Hgd! 8$]^`gd!=>BMNO[cov|̫ӫ+,-.Pivʬˬլ֬جެ߬ h)h!\h8h!\hlh!\ hAh! h)h!h!h]h!5 h!5h(j'hc5Lv̫, 8$]gd! !8$]gd! !8$]^`gd! 8$]^`gd!ʬˬج APQ\zgdc !8$]^`gd! !8$]gd! 8$]^`gd! 8$]gd!APQ\ivzʭ˭̭֭׭߭ &'Qjwƽuhwh!\^Jh%Olh!\^Jhdh!B*\^Jphh!B*\^Jphh)h!B*\^Jphh)h!\^Jh)h!^Jhugh!^J hDh! hAh!h]h!5 h!5 hch+h!hc h)h!.ʭۮܮ '5Zhv !8$]^`gd! 8$]gd! 8$]^`gd! !8$]gd!֮׮ٮۮܮ߮ '5OQTWZ\behjvwĽϵϵϵϵϮϗh)h!7^J h`2h!h)h!7 hl0h!hl0h!\ hdh!h)h!\ h_^h! h}h!h! h)h!hIh!\^J h!\^Jh)h!\^Jh)h!B*\^Jph4̯+Hklmnopq !8$]^`gd! !8$]gd! 8$]gd! 8$]^`gd!Ưǯȯ̯ͯԯկ֯ׯٯܯޯ߯ +HQjklmnopqrsuưϰѰ¾h)h ~^J h)h ~ h8h ~h8h ~5hchAh!;h! hAh!h)h!7 h)h!h)h!^Jhl0h!\h)h!7^J>qrsưްy] 8$]^`gd ~ !8$]^`gd ~ 8$]gd ~ !8$]gd ~ 8$]gd: 8$]gd! !8$]gd! ѰҰӰ԰ܰݰް  !NglmntӱԱܱݱN]^gtz{ӲԲܲݲNgnʼݵ𙙙h)h ~\^JaJh)h ~\h)h ~7 hugh ~h&'mh ~KH\^JaJh)h ~KH\^JaJ h ~;h ~h)h ~; h-h ~ h)h ~h8h ~^J<ް lm]^z{гѳ !8$]^`gd ~ !8$]gd ~ 8$]gd ~ 8$]^`gd ~ntϳгѳӳԳܳݳNcegt´ôŴѴҴӴԴܴݴȼԳߦߦߦ h0Gh ~ h)8#h ~ hYh ~ hH+h ~ h8h ~h ~h_Kfh ~^Jh_h ~^Jh_h ~\^JaJh_Kfh ~\^JaJh_Kfh ~^JaJ h_Kfh ~ h)h ~h ~^JaJh)h ~^JaJ3ôѴ!"#$()5} !8$]gd(@ 8$]gd(@ 8$]gd: 8$]gdT 8$]^`gd ~ 8$]gd ~ !"#$'()5NgtеӵԵܵݵ޵FGNQRZ[dgt|ӶԶܶݶ234=>ABJ hh(@ h0Gh(@h(@ h_Kfh(@ h8h(@h8h(@5h hT\^J h0Gh ~h ~L5FGZ[d|34P !8$]^gd(@ !8$]gd(@ !8$]^`gd(@ 8$]gd(@ 8$]^`gd(@JMNOPRUV^acdegtӷԷIJKN_`abcdefghrwhuh(@\^J h(@\^J hk~h(@ hqh(@ h_Lh(@hVh(@5 h(@5hT&bh(@5>*hT&bh(@5 h_Kfh(@ hh(@ h0Gh(@h(@@PdetJK_`ab !8$]gd(@ 8$]^`gd(@ 8$ ]^` gd(@ 8$]gd(@ !8$]^`gd(@bcdef !8$]^`gd(@ 8$]gd !8$]gd 8$]gd(@ !8$]gd(@ӸԸ)*+,8NӹԹ"#NqȺӺԺ྾ h%Olh(@ hwh(@ h)h(@h_Kfh(@@\^Jh_Kfh(@\ h_Kfh(@h(@hT@h(@5hhuh\^J h(@5E+,8#qȺ?@ 8$]gd(@ !8$]gd(@ !8$]^`gd(@ 8$]^`gd(@"LNlӻԻ"NӼԼ">?@ENXZĽӽԽ"NҾӾԾ hugh(@ hh(@h)h(@5 heNh(@ hWrh(@ h%Olh(@h(@ h)h(@P@ĽӾԾ @ABCwdd XpP gdV 8$]gd(@ !8$8]^8`gd(@ !8$]^`gd(@ !8$]gd(@  !]gd(@ !8]^8`gd(@ "?@ABCFGHNWӿԿ &:N_s Nƾ췷 hW/h(@h>h(@5hRhRh(@5 hT>h(@hvh(@5h(j'hV5 h5yhVh(@ h)h(@h)h(@5HCGHW&:_s !8$8]^8`gd(@ 8$]^`gd(@ 8$]gd(@ $HN\ N ,>?EFHIhcX4^JaJ h)hcX4hcX4h?$qhcX45hVh(@ h)h(@hW/h(@>*hW/h(@5 hv h(@ hW/h(@H$H\ 8$]gdV 8$]^`gd(@ !8$8]^8`gd(@ 8$]gd(@,NO[pq< !8$]^`gdcX4 !8$]gdcX4gdcX4 8$]^`gdcX4 8$]gdcX4IJMNO[opqst ;<=HIJMNQR]hcX45>*\hVhcX45 hcX45\hNnhcX45>*\hNnhcX45\hcX4\^JaJhcX4hW/hcX4^J hcX4^J h8shcX4h8shcX4^Jh)hcX4^Jh2+hcX4>* h)hcX48<=QR]@Anopqrst 8$gdcX4 8$]^`gdcX4 8$]gdcX4BHLMQ=>?@ABHLMQ`acdfgiklmnopqrstuvⷷ h)hcX4 hVhcX4h]hcX45hhV hcX45hcX4 hAhcX4hAhcX4\^JaJ hcX45\hAhcX4\hVhcX45hNnhcX45\hNnhcX45>*\<9:Z[n$%3DE[i 8$]^`gdcX4 8$]gdcX4 8$]gdV*89:HLMPQUWYZ[jnw$%&345HKLPjow|򪡗h)hcX4B*\^Jphh)hcX4\^Jh)hcX4^JhihcX4^J hihcX4 h 3hcX4h)hcX45\hMhcX4\hhcX4\h)hcX4\ hhcX4h)hcX45 h)hcX4 hVhcX40|}$DEHKLP[ijuwֶvvvh^hcX4^J hkBhcX4h^hcX4\hkBhcX4\ h^hcX4hcX4 h)hcX4 h 3hcX4 hcX4\^Jh)hcX4\^JhhcX45\^Jh/8hcX4\^Jh)hcX4B*\^JphhughcX4B*\^JphhcX4B*\^Jph.iukl !8$]gdcX4 8$]gdV 8$]gdcX4 8$]^`gdcX4$+,-HKLPXcjklvwyz~̾ӠӠh^hcX45\ h8shcX4 hcX45hV hV\^J hcX4\^J hThcX4 hS0hcX4 hVhcX4 h^hcX4hVhcX4^Jh =WhcX4^JhcX4 h*y<hcX4h^hcX4^J;+HKLPYZ[qstuvwy !$?@HJKObcdejqrstwh/KAhcX4\^J h/KAhcX4 hs+hcX4 hcX4\^J hcX4^J hhcX4 h+eBhcX4hcX4 h^hcX4JZ[tu@cdr 8$ ]^` gdcX4 XpP H]HgdcX4 8$]gdcX4 !8$]gdcX4 !8$]^`gdcX4 /0?+,Rf{|} !8$]gd:" !XP $gdcX4 8$]gdcX4  8(`$]^`gdcX4 8$]^`gdcX4 !$./01>?@AHJKOjuw*+,?@HIJOPQRefz{|}~'(HIJY\]jhcX4^JaJhVhuh:"\^J hcX4\^JhAhcX45hcX4 hcX45R}~pq !8$]gdcX4 !8$]^`gdcX4 8$]^`gdcX4 8$]gdcX4 8$]gdV'(HIJY\]jopqs~շշշhAhcX4\h.ahcX45\^JaJhVhcX45h.ahcX45>*\h.ahcX45\ hcX4^J hcX45\ hcX4\hcX4H*+,-./01234567 8$]gdcX4 !8$]gdcX4 !8$]^`gdcX4 8$]^`gdcX4 "%'()*+,-./0123456789:;<=>FHIJNVWXY[\]^`no +,FHɻhcX4>*^JaJ hcX45hcX4 hcX4^J hcX45\hAhcX4\h.ahcX45>*\h.ahcX45\hVhcX45J789:;<WXY]^o !8$]^`gdcX4$ XP 8$]gdcX4 8$]gdV !8$]gdcX4 8$]gdcX4 ,R^jv=>R^j 8$]gdcX4 !8$]gdcX4 !8$]^`gdcX4 8$]^`gdcX4HIJQRW]^`dgijuvx}FHIJWFHIJW <=>?BCHIPQR]^`ijklm hcX4hcX4 hcX45hcX45\^J h)hcX4 hcX4^J hcX4\hcX4Tjklmqr"34| !8$]gdcX4 !8$]^`gdcX4 8$]^`gdcX4gdcX4$ XP 8$]gdcX4 8$]gdcX4mpqr!"2349FGHIJWqrs23EFGHIJWXYlm hcX45>* hcX45hcX4^JaJhcX4hcX45>*^JaJh.ahcX4>*\^JaJR4rs3FYmyyyyy !8$]^`gdcX4 8$]gdcX4 8$]^`gdcX4$ XP 8$]gdcX4 !8$8]^8`gdcX4  -./7Ϳҁrjh5UmHnHuh;]h0J5h0J5CJh h5CJh0JCJh0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5he'jhe'Uh(@h(@\ hAhcX4hhcX4\hcX4, $]$ XP 8$]gdcX4 !8$]gdcX4 8$]^`gdcX4 !8$]^`gdcX4 .[\]_&s"  !h]%*$]^`% %*$]^`% h0*$]^`0 !$&dP]  !$] ! $&dP]7OPQWXYZ[\]^_`fg &7| ,24ĭ~~~~~~~~~~~ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhh;]hCJhT0J5CJmHnHujh0J5CJUh0JCJh0J5CJ147Ts "7 /7@ABHI} 7X^` 07OhCJOJQJh LhCJH*KHhh0JCJ hCJ h6CJR@AOw !$]gd> !$]gdIG !h]gdIG%*$]^`%gd %$d*$N]^`%gd  !$]  !$]  !h] O 7cik %&'()*+789h5CJ\hT0J5CJ\mHnHuh0J5CJ\jh0J5CJU\ h5 h0J5h hHCJ hxHCJh0JCJ h6CJ hCJ;)*+9EFGUuuu%*$]^`%gdh# %$d*$N]^`%gdh# ! $&dP] $ $]a$ !$&dP]  !$] !$]gdIG 9:;ABCDEFGHNO 7^df 67U 7ioǻ hh#6CJhh#CJOJQJ hh#CJh Lhh#CJH*KHh h5CJhW0J5CJmHnHuh0J5CJjh0J5CJUh0JCJ@oq  7TZ\| 57;=]̵ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhhh#hCJ hWCJ hCJ hQ}2CJhh#0JCJ hh#6CJ hh#CJ4,w  !h]%*$]^`% %*$]^`% h0*$]^`0gdwO !$]gdh# !$]gdh# !h]gdh#%*$]^`%gdh#  ,7 7FLNn $͵ͮ h5CJhH+0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hh0JCJ h6CJ hCJD %012$ $&dP]a$gd0$$ $]a$gd0$ !$&dP]  !$]  !$]  !h]$%&,-./0123457;<pvx 7KQSs #7ɲ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuh h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5324B xq%*$]^`%gdh# %$d*$N]^`%gdh#  !$]  !$]  !h]%*$]^`% %*$]^`% h0*$]^`0 7B 7V\^~ 7FLNn !')7Ix hh#6CJhh#CJOJQJ hh#CJh Lhh#CJH*KHhh0JCJ h6CJ hCJM 7z ,247Tstu̾ؖ h^3 CJh^3 CJH*KH h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hhh#hCJ hCJhh#0JCJ hh#6CJ hh#CJ7xstuv %$d*$N]^`%gd^3  !$&dP]  !$]gdh !$]gdh# !$]gdh# !h]gdh#%*$]^`%gdh#  ,-379;[cp ,-67cdep ,-7cgmop !,-7A_`abcph^3 0JCJ h^3 6CJ h^3 CJh^3 CJOJQJWe`ab $ $]a$h]h ! $&dP] $]gd } !$]gd^3  !$]gd^3  h]gd^3 %*$]^`%gd^3 żŭťӏtkbh^3 CJH*KHh5CJ\hT0J5CJ\mHnHuh0J5CJ\jh0J5CJU\ h5CJh0JCJhh#0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hh^hhCJ h^3 CJh^3 0JCJ h^3 0J"ojklgd } !$]gd^3  !$]gd^3  h]gd^3 %*$]^`%gd^3  %$d*$N]^`%gd^3 $ $&dP]a$gd  .17=CEbeo  .17@bno .17boqwy #)+.17Kbijkloh^3 0JCJ h^3 6CJ h^3 CJh^3 CJOJQJY 013BDHJͿͿم{tt h^3 6CJh^3 CJOJQJhoh^3 CJH*KHhcS0J5CJmHnHu h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hhh#hCJ h^3 0J hg;`CJ h^3 CJh^3 0JCJ-tpqr !h]gd^3 %*$]^`%gd^3  %$d*$N]^`%gd^3  $]gdv5 ! $&dP] $]J`cj#%013DE`ct013D`cv|~(.013DP`cpqr hg;`CJh^3 0JCJ h^3 CJ h^3 6CJZrD@ABy{ !$]gd } !$]gd } !h]gd }%*$]^`%gd } %$d*$N]^`%gd }gd } !$]gd^3  !$]gd^3 /:/D/FLNn /@ABalxyh0JCJ h6CJhCJOJQJ hCJh5CJH*KHhhcShCJ hg;`CJM&/04[h/04[hܽ h^3 6CJh^3 CJOJQJ h^3 CJh=h^3 CJH*KHaJ h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5h hCJ<0y,-.er !$]gd^3  !$]gd^3  !h]gd^3 %*$]^`%gd^3  %$d*$N]^`%gd^3 gdv5$ $&dP]a$gd$ $]a$gdv5 /0248:Z[hy ,-./04MX[abdeh̾ h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hh"hCJ hg;`CJh^3 0JCJ h^3 6CJ h^3 CJ>612 h]gdXg%*$]^`%gd.b %$d*$N]^`%gd.b $ $]a$ ! $&dP] $]gdo  +,+6+8ݾ h.b6CJh.bCJOJQJ h.bCJh.b5CJH*KHh h5CJh"0J5CJmHnHuh0J5CJjh0J5CJUh0JCJ h5 h0J5<8>@`+123?]gij޻xq h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhhXghCJhXghXgCJhXghXg0JCJ h>CJ hg;`CJhXg0JCJ hXgCJ h.bCJ h.b6CJ,23j_   [    G y   !$]  !$]  !h]%*$]^`% %*$]^`% h0*$]^`0gdo !$]gd> h]gdXg' _               ' e k m               ' < [                 ' / : F G h y z       h0J5CJjh0J5CJU h5 h0J5hh0JCJ hCJ h6CJIy z          t !uu%*$]^`% %*$]^`% h0*$]^`0$ $&dP]a$ $ $]a$gdv5$ $&dP]a$gdv5$ $]a$gdv5                              ' t             ؝unnnnnnnnn h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhT0J5CJmHnHuh0J5CJ h5 h0J5h h5CJjh0J5CJUhc0J5CJmHnHu+   !'z#')+Kj'>IUVw'D h.b6CJh.bCJOJQJ h.bCJh.b5CJH*KHhh0JCJ h6CJ hCJNjVD: !h]gdo%*$]^`%gd.b %$d*$N]^`%gd.b  !$]  !$]  !h]%*$]^`%'JPRr': "$%'EFOPQ^_`fgijklmz{ h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5h hg;`CJh0JCJ hCJ h.b6CJ h.bCJ@%PQ_klm{Ku%*$]^`%gd.b %$d*$N]^`%gd.b $ $]a$ ! $&dP] $]gdo !$]gdo !$]gdo {|}#K#QWYy"#AǼ h.b6CJh.bCJOJQJ h.bCJh.b5CJH*KHh h5CJhc0J5CJmHnHuh0J5CJjh0J5CJUh0JCJAA,[\^%r!%*$]^`% %*$]^`% h0*$]^`0gd !$]gdU= !$]gdU= h]gdU=%*$]^`%gd.b#+,LMZ[\]^_ef#%{ǰ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhhU=hCJ hcCJhXghU=0JCJhU=0JCJ hU=CJ h.b6CJ h.bCJ2#+13Sr!#  #.?@MNOUVXYZ[\]͵ͭ h5CJh0JCJhU=0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hh0JCJ h6CJ hCJA ?@N[\]kwxy$ $&dP]a$gd $ $]a$ ! $&dP] $]  !$]  !$]  !h] ]jklrsuvwxyz#:#@FHh#· h 6CJh CJOJQJ h CJh 5CJH*KHh h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5?y:0 J K Y e f w ! $&dP] $]gd !$]gdU= !$]gdU= h]gdU=%*$]^`%gd  %$d*$N]^`%gd #0   # ; < I J K X Y Z ` a c d e f g t u v w } ~   wh>0J5CJmHnHuh0JCJ h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hhU=hCJ hcCJhXghU=0JCJhU=0JCJ hU=CJ h 6CJ h CJ.f g u    E!!";####&$U$} !$]gd> !$]gd> h]gd>%*$]^`%gd  %$d*$N]^`%gd  $&dP] $ $]a$                   #!E!!!!!!!!!!!!!!!!#"K"Q"S"s""""""""""""""###;##################$#$%$h>0JCJ h>CJ h 6CJh CJOJQJ h CJh 5CJH*KHh h5CJL%$&$F$G$T$U$V$W$X$Y$_$`$$$$$$$$$$$$$$$%#%o%u%w%%%%%%%%%%%%%&#&%&'&G&f&&&&&&&&&Խ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhhU=h>CJ h CJ hcCJh>0JCJhXgh>0JCJ8U$V$X$%%f&''''',(-(;( $ $]a$  !$]  !$]  !h]%*$]^`% %*$]^`% h0*$]^`0gd> &&&&&&&'#'z'''''''''''''''''''(#(,(-(:(;(<(B(C(E(F(G(H(I(J(P(Q(((((((((((̴̭梜 h 6CJh CJOJQJ h CJh 5CJH*KH h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hh0JCJ hCJ h6CJ6;(G(H(I( ))W*+++++, !$]gdXg !$]gdXg h]gdXg%*$]^`%gd  %$d*$N]^`%gd $ $&dP]a$gd ((((( )#)`)f)h)))))))))))))***#*8*W***************+#+k+q+s++++++++++++++++++ , ,,,,#,(,), h5 h0J5hhXghCJ hcCJhXghXg0JCJhXg0JCJ hXgCJ h 6CJ h CJG,,),5,6,7,E,Q,R,S,--a. //%*$]^`%gd-[ %$d*$N]^`%gd-[h]h ! $&dP] $] %*$]^`%gd6=),*,0,1,3,4,5,6,7,D,E,F,L,M,O,P,Q,R,S,T,Z,[,,,,,,,,,,,,,,,-#-j-p-r-------------. .".#.B.ϩ h-[6CJh-[CJOJQJ h-[CJh-[5CJH*KHhT0J5CJmHnHu h5 h0J5h h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU9B.a.............. /#/u/{/}////////////////00#0$0%0&0'0(0.0/0c0i0k0000ǰ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhhThCJ hcCJhXghT0JCJhT0JCJ hTCJ h-[6CJ h-[CJ2////$0%0'001522333yy  !h]%*$]^`% %*$]^`% h0*$]^`0 %*$]^`%gd6= !$]gdT !$]gdT h]gdT 0000000000#1>1D1F1f11111111111112#252222222222222222#3I3O3Q3q333333333333333333334 4 444h0J5CJjh0J5CJU h5 h0J5hh0JCJ h6CJ hCJI3333 444445%66777}} !h]gdU%*$]^`%gdU %$d*$N]^`%gdU$ $&dP]a$ $ $]a$  !$]  !$]444444444#4S4Y4[4{4444444444444#5.54565V5555555555555556#6%6666666666666666#797?7A7ƼƵƵƯ hU6CJ hUCJ h$=6CJh$=CJOJQJ h$=CJh Lh$=CJH*KHh h5CJjh0J5CJUhT0J5CJmHnHuBA7a7777777777777777777777777788888888888888#8%8&8Z8úëäúÕä݉yh5gCJOJQJ h5gCJh Lh5gCJH*KHhT0J5CJmHnHu h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hhUhCJhU0JCJ hUCJ hU6CJ,77777888888889u%*$]^`%gd5g %$d*$N]^`%gd5g $]gd ! $&dP] $]gd8C !$]gdU !$]gdU Z8`8b8888888888888#959;9=9]9999999999999 :#:,::::::::::::::::#;@;F;H;h;;;;;;;;;;;;;;;;;;;,jh5@CJH*KHUmHnHuh hCJ h CJh5g0JCJ h5gCJ h5g6CJH9,::;;;;;;;<f=>>h?%*$]^`% %*$]^`% h0*$]^`0gdaR !$]gd5g !$]gd5g !h]gd5g%*$]^`%gd5g;;;;;;;;#<.<4<6<V<<<<<<<<<<<<===#=7=f===============>#>n>t>v>>>>>>>>>>>>> ?#?&?(?H?h?i?j????????????h0JCJ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KHOh?i?j????????? @ @ @$ $&dP]a$gd$ $]a$gdgdv5 $&dP]gdv5 $]gdv5  !$]  !$]  !h] ?????????????????@@@@ @ @ @ @ @@@#@H@N@P@p@@@@@@@@@@@@#A)A+AKAzA{{{{ h6CJhCJOJQJ hCJh5CJH*KH,jh5@CJH*KHUmHnHuhT0J5CJmHnHu h5CJhEFEGFGGG~GGGGGGGG $]gdgdv5 $&dP]gdv5 $]gdv5gdaR !$]gdR^R}RRRRRRRRRRRRRS#S0S1S2SQS\ShSiSSSSSSSSSSSSSSSSSSSSSSSS#TWTXTZT_TTTTTTTTTTTTTTTTTTUU#UZU^U hcX46CJhcX4CJOJQJ hcX4CJhcX45CJH*KHhh0JCJ h6CJ hCJNSSXTUUNVWWW9WdWeWsWWs $&dP] $]gdcX4 !$]gdcX4 !$]gdcX4 h]gdcX4%*$]^`%gdcX4 %$d*$N]^`%gdcX4  !$] ^U_UdUfUUUUUUUUUUUUUUUUUV VV#V/VMVNVZV_VVVVVVVVVVVVVVVVVVVWWWW#W,W5W7W8W9WYWZW^W`WcWdWeWrWsWtWzW{W˽h0J5CJjh0J5CJU h5 h0J5hhThcX4CJ hcX40JhcX40JCJ hcX4CJ hcX46CJD{W|W}W~WWWWWWWWWWWWWWWWWWWWWWWWWWWXX^X|XXXXXXXXXXXXXX YYdYjYlY|YYYYYYة hU=6CJhU=CJOJQJ hU=CJhU=5CJH*KHh[?[_[`[m[n[o[p[q[r[x[y[|[[[[[[[ǰ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhhU=hCJ hcCJhXghU=0JCJ hY$TCJhU=0JCJ hU=6CJ hU=CJ2?[n[o[q[2\\](^^^^_E_F_T_ $] !$]gdv5 !$]gdv5  !h]%*$]^`% %*$]^`% h0*$]^`0gdN !$]gdU=[[[[[[[[\2\|\\\\\\\\\\\\\\]8]>]@]`]|]]]]]]]]]]]]] ^^(^|^^^^^^^^^^^^^^^^^^____5_E_F_S_T_U_[_\_h0J5CJjh0J5CJU h5 h0J5hh0JCJ hCJ h6CJJ\_^___`_a_b_c_p_q_r_x_y_{_|_}_~__________________`B`|``````Е}wmwwwfwfwwwwwwwwwwfwf h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhT0J5CJmHnHuh0J5CJ h5 h0J5h h5CJh0JCJjh0J5CJUhg?gAgBgCgDgEgRgSgTgZg[g]g^g_g`gagbghgig|gggggggggggggh"hxh|h~hhhhhhhhhhhhhi(i.i0iPioi|iΨ hU=6CJhU=CJOJQJ hU=CJhU=5CJH*KHh ! $&dP] $]gdv5gd3( !$]gd8L !$]gd8L h]gd8L%*$]^`%gd8L !./0679:;<=>?EFz~Եԩ疈wk`ZPZI hl6CJhlCJOJQJ hlCJhl5CJH*KHhNh5CJaJ hLնuu %*$]^`% h0*$]^`0gd !$]gdl !$]gdl h]gdl%*$]^`%gdl %$d*$N]^`%gdl NTVvz~ն+13Sz~۷"z~̸7=?_z~ǽǶǶǶǶǶǶǶǶǶǶ h6CJhCJOJQJ hCJhCJH*KH\h5@CJH*KH,jh5@CJH*KHUmHnHuhHն"̸ $ $]a$ ! $&dP] $] !$]gdv5 !$]gdv5  !h] *$]^%*$]^`%ٹ !"#$%&,ԼԴԞԭzoh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhT0J5CJmHnHu h5CJh0JCJhZ[djls+.1256>?EGZ[gs+.1256>Z[s+.1256 h!6CJh!CJOJQJ h!CJh!5CJH*KHhV6>JPRZ[rs !"#)*̾̐h0J5CJ\jh0J5CJU\ h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5hhlh!CJ h!0Jh!0JCJ h!6CJ h!CJ."./0>%*$]^`%gd! %$d*$N]^`%gd! $&dP]gd $]gd ! $&dP] $]gd!*,-./0136789:;=>Fbclrt{369:=>FGMObco{369:=>Fbc¸±±±±±± h!6CJh!CJOJQJ h!CJh!5CJH*KHhh5CJ\jh0J5CJU\hH+0J5CJ\mHnHuFc{369:=>FRXZbcz{   >hCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhhlh!CJ h!0Jh!0JCJ h!6CJ h!CJ9plmn{ !$]gdv5  !h]%*$]^`% %*$]^`% h0*$]^`0gd! !$]gd! !$]gd! h]gd!>DFfjr !Afjpr fjrxz $*,Lfjlmnrjh0J5CJU\ h5 h0J5hh0JCJ hCJ h6CJNc_%*$]^`%gdaR %*$]^`%gdaR h0*$]^`0gdaR !$ $&dP]a$gd$ $]a$gd !$]gdv5  179Yfjr  4cfjrɲ h6CJhCJOJQJ hCJh5CJH*KHh5@CJH*KH,jh5@CJH*KHUmHnHuhh5CJ\hT0J5CJ\mHnHujh0J5CJU\h0J5CJ\3 efjkmr ?_`afjr .?BHIXw h!6CJh!CJOJQJ h!CJh!5CJH*KHhh0JCJ h6CJ hCJN_`a8345l| !$]gd! h]gd!%*$]^`%gd! %$d*$N]^`%gd!gdaR !$]gdaR !$]gdaR !h]gdaR  78?BHIXw:?@BHIXbw2345?ABHIX_hjklw h5 h0J5hhlh!CJ h!0Jh!0JCJ h!CJ h!6CJPl@qq%*$]^`%gd! %$d*$N]^`%gd! $&dP]gd $]gd ! $&dP] $]gd! !$]gd! 6GJPQôυunnn h!6CJh!CJOJQJ h!CJh!5CJH*KHh5CJ\hl0J5CJ\mHnHuh0J5CJ\jh0J5CJU\ h5 h0J5h h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU+Q`?@GJPQ`BGHJPQ`j:;<=GIJPQ`gprst h!0Jh!0JCJ h!6CJ h!CJZ;<=tcY  yy !h]gd:%*$]^`%gd: %$d*$N]^`%gd:gd! !$]gd! !$]gd! h]gd!%*$]^`%gd!bcfnbfinoq:Ybfn  - h6CJhCJOJQJ hCJh=hCJH*KHaJhhlh!CJ h!CJO-8DEbfntu R b f n               X ^ ` b f n Ӹӯ򓓓򓓓򓓓 h6CJhCJOJQJh5CJH*KHh5CJ\hT0J5CJ\mHnHuh0J5CJ\jh0J5CJU\ h5 h0J5h hCJh0JCJ:EtuR   H  xxxx%*$]^`%gdaR %$d*$N]^`%gd: !$ $&dP]a$gd$ $]a$gdgd: !$]gd: !$]gd: n              ) H b f n                  ' 3 4 U b e f g i l m n o p q s t |               & ' L i l o p s t |  h!6CJh!CJOJQJ h!CJh!5CJH*KHhh0JCJ hCJ h6CJM   4 e f '  t !$]gd! h]gd!%*$]^`%gd! %$d*$N]^`%gd! !$]gdaR !$]gdaR !h]gdaR | }               -35LUilopst|Lilopst|()/456C h0J5hhlh!CJ h!0Jh!0JCJ h!6CJ h!CJQ56DPQR`lmn/|qq%*$]^`%gd! %$d*$N]^`%gd! $&dP]gd $]gd ! $&dP] $]gd! !$]gd! CDEKLNOPQR_`acghjklmnoqtuvwxy{|Ʉ~~~t~~~~~~~~~m~mm~~~~ h!6CJh!CJOJQJ h!CJh!5CJH*KHh5CJ\hT0J5CJ\mHnHuh0J5CJ\jh0J5CJU\ h0J5h h5CJhT0J5CJmHnHuh0J5CJjh0J5CJU h5*./Tqtwx{|5;=T]qtwx{|$%Tqtwx{| 01 h!0Jh!0JCJ h!6CJ h!CJZ|%=>Lyy !h]gd:%*$]^`%gd: %$d*$N]^`%gd:gd! !$]gd! !$]gd! h]gd!%*$]^`%gd!17<=>?EF]aizU[]ai}  -L]ai]`afhi h6CJhCJOJQJ hCJh=hCJH*KHaJhhlh!CJ h!CJL &')*+,-.45]aioqDJL]ailӸӯ hT6CJhTCJOJQJ hTCJh=hTCJH*KHaJh )hh5CJ\hT0J5CJ\mHnHuh0J5CJ\jh0J5CJU\ h5 h0J5h hCJh0JCJ3+,-;xxxx%*$]^`%gdT %$d*$N]^`%gdT !$ $&dP]a$gd3'"$ $]a$gd3'"gd: !$]gd: !$]gd: ;]aiOUW]aiw ƸhT0J5CJmHnHuh0J5CJjh0J5CJU h5 h0J5h )hThCJ hcCJ h ~CJhT0JCJ hT6CJ hTCJ>*yyyy%*$]^`%gd(@ %$d*$N]^`%gd(@ ! $&dP] $] !$]gdT !$]gdT !h]gdT#$X^`hiu39;[hiu *hiu>DFfhiuh(@0JCJ h(@6CJh(@CJOJQJ h(@CJh Lh(@CJH*KHh )h h5CJN    " # $ $ $&dP]a$gd<$ $]a$gd< ! $&dP] $] !$]gd(@ !$]gd(@ !h]gd(@              ! " # $ % + , [ _ ` ˳ˬٙ~ujdZdddhVCJOJQJ hVCJhV5CJH*KHhV5CJ\hT0J5CJ\mHnHuhV0J5CJ\jhV0J5CJU\hV hV5CJhV0J5CJmHnHuhV0J5CJjhV0J5CJU hV5 hV0J5h )h(@hCJ h(@CJh(@0JCJ#` f g h           !;!A!C![!_!c!g!!!!!!!!!!!!""2"["_"g""""""""""""""#F#L#N#[#_#g#n####################h Lh(@CJH*KHhVhlhVCJhXghV0JCJhV0JCJ hVCJ hV6CJN$  !2""######$`%|j%*$]^`%gd(@ %$d*$N]^`%gd(@gdaR !$]gdl !$]gdl h]gdl%*$]^`%gdl %$d*$N]^`%gdl ####$.$4$6$>$?$K$V$$$$$$$$$$% %%%1%>%?%K%`%%%%%%%%%%%%%%&&>&?&K&b&h&j&&&&&&&&&&&&''''<'>'?'K'['\']'|'''''''''''''h(@hVCJh(@0JCJ h(@6CJh(@CJOJQJ h(@CJU`%&&['\']''''''''' $]gd< ! $&dP] $]gd: !$]gd(@ !$]gd(@ !h]gd(@%*$]^`%gd(@ '''''''''''''''''''''''''''((6(<(>(F(G(S(^((((((((𴩴~~t~m~mmmm~~~~~~~ h(@6CJh(@CJOJQJ h(@CJh Lh(@CJH*KHhV5CJ\hV0J5CJ\mHnHuhV0J5CJ\jhV0J5CJU\ hV5CJhT0J5CJmHnHuhV0J5CJjhV0J5CJU hV5 hV0J5hV*''''(h)**c+d+e++++ !$]gd(@ !$]gd(@ !h]gd(@%*$]^`%gd(@ %$d*$N]^`%gd(@ ! $&dP]gd< ((())))9)F)G)S)h)))))))))))))**F*G*S*j*p*r************++"+$+D+F+G+S+c+d+e++++++++++++++++++++,,hVCJOJQJ hVCJh=hVCJH*KHaJhVh(@hVCJh(@0JCJ h(@6CJ h(@CJJ, ,,.,U,Y,a,,,,,,,,,,,,- -8-U-Y-a--------------.:.@.B.U.Y.a.b.............//4/5/6/U/Y/`/a/l/m//////////hV0J5CJ\jhV0J5CJU\ hV5 hV0J5hVhV0JCJ hVCJ hV6CJL+,8--.4/5/6/m/////r$ $&dP]a$gd<$ $]a$gd<gd: !$]gd: !$]gd: !h]gd:%*$]^`%gd: %$d*$N]^`%gd: /////////////// 0 00000B0v0w0y000000000000 1 1111#1$1B1y1}1111111111111 2 2222&2,2.2B2N2l2m2y2¸±±±±±±±± hcX46CJhcX4CJOJQJ hcX4CJhcX45CJH*KHhVhV5CJ\jhV0J5CJU\hT0J5CJ\mHnHuF///w0$11m23 3!3X3333 $]gdcX4 !$]gdcX4 !$]gdcX4 h]gdcX4%*$]^`%gdcX4 %$d*$N]^`%gdcX4 ! y222222222223 3 333333 3!3-3B3K3T3V3W3X3x3y3}3333333333333333333̾ hV5 hV0J5h}Ulh) h)5CJhT0J5CJmHnHuh)0J5CJjh)0J5CJU h)5 h)0J5hVhThcX4CJ hcX40JhcX40JCJ hcX46CJ hcX4CJ033333333}4*55s6%7&7'7 h]gdcX4%*$]^`%gdcX4 %$d*$N]^`%gdcX4 $&dP]gd< $]gd< ! $&dP]33333333333333333444444 4H4|4}444444444444455555)5*5H55555555555555566666Ƚ hcX46CJhcX4CJOJQJ hcX4CJhcX45CJH*KHhVhV5CJ\h0J5CJ\mHnHuhV0J5CJ\jhV0J5CJU\A6,62646H6T6r6s666666666666777777$7%7&7'737H7Q7Z7\7]7^7~77777777777777777777777K8M8Q8Y888888888ĺijijijij hV6CJhVCJOJQJ hVCJh=hVCJH*KHaJh}UlhThcX4CJ hcX40JhcX40JCJ hcX46CJ hcX4CJF'7^777K889A::::-;X;Y;{y !$]gdT !$]gdT !h]gdT%*$]^`%gdT %$d*$N]^`%gdTgdcX4 !$]gdcX4 !$]gdcX4 8888888M9Q9W9Y9y99999999999::":A:M:Q:Y:::::::::::::::::; ;,;-;M;Q;W;X;Y;f;g;h;n;o;q;r;s;t;u;;úëä hV5CJh0J5CJmHnHuhV0J5CJjhV0J5CJU hV5 hV0J5hVhThVCJhV0JCJ hVCJ hV6CJ@Y;g;s;t;u;;;;;R<<=H>>%*$]^`%gdaR %$d*$N]^`%gd:$ $&dP]a$gd<$ $]a$gd< ! $&dP] $] ;;;;;;;;;;;;;;;;;;;;;;;;;;M<Q<R<Y<<<<<<<<<<<<<<<M=Q=X=Y=^=`===========>> >)>ø hV6CJhVCJOJQJ hVCJhV5CJH*KHhVhV5CJ\hT0J5CJ\mHnHuhV0J5CJ\jhV0J5CJU\ hV5?)>H>M>Q>Y>>>>>>>>>>>>>>>>?&?2?3?M?Q?S?Y?^?_?`?f?g?p?q????????????@ @"@+@H@T@p@q@v@|@~@@@@@@@@@@@"A&A+A,A.AHANATAlAmApAqA hcX46CJhcX4CJOJQJ hcX4CJhcX45CJH*KHhVhV0JCJ hV6CJ hVCJN>>>3?^?_? @@mABBBBC !$]gdcX4 h]gdcX4%*$]^`%gdcX4 %$d*$N]^`%gdcX4 !$]gdaR !$]gdaR !h]gdaR qAAAAAAAAAAAABB"B+BHBTBpBqBBBBBBBBBBBBBBBBBBBBCC!C"C&C(C+C,C-C:C;C*T@T " Heading 2"$@& XP 5>*R@R  Heading 3"$@& XP 5DD  Heading 4$@&CJOJQJuZZ  Heading 5*$ XP @&]5bb  Heading 62$ XpP X@&^X`5jj  Heading 7:$ XpP  @&]^` 5^^  Heading 8-$ 8$@&]5F F  Heading 9 $@& >*uDA`D Default Paragraph FontViV  Table Normal :V 44 la (k (No List 4@4 Header  !F/F a[W Header CharOJQJ_HmH sH tH 4 @4 Footer  !.)@!. Page NumberlC@2l Body Text Indent2 XP 0d.^`0`TB` Block Text1 XP H]^H`bR@Rb !Body Text Indent 2$ XP ^jSbj Body Text Indent 3, XpP 8^8`F/qF s Char Char3OJQJ_HmH sH tH B' B Comment ReferenceCJaJ@@  Comment Text mHsHtHB/B Comment Text CharOJQJ@j@ Comment Subject5\N/N Comment Subject Char5OJQJ\PP  Balloon TextCJOJQJaJmHsHtHN/N Balloon Text CharCJOJQJ^JaJbob [nDefault 7$8$H$-B*CJOJQJ^J_HaJmH phsH tH 6/6 Xg Footer CharOJQJN/N 8LBody Text Indent 2 CharOJQJB/!B 8LHeading 2 Char5>*OJQJPK![Content_Types].xmlN0EH-J@%ǎǢ|ș$زULTB l,3;rØJB+$G]7O٭VGRU1a$N% ʣꂣKЛjVkUDRKQj/dR*SxMPsʧJ5$4vq^WCʽ D{>̳`3REB=꽻Ut Qy@֐\.X7<:+& 0h @>nƭBVqu ѡ{5kP?O&Cנ Aw0kPo۵(h[5($=CVs]mY2zw`nKDC]j%KXK 'P@$I=Y%C%gx'$!V(ekڤք'Qt!x7xbJ7 o߼W_y|nʒ;Fido/_1z/L?>o_;9:33`=—S,FĔ觑@)R8elmEv|!ո/,Ә%qh|'1:`ij.̳u'k CZ^WcK0'E8S߱sˮdΙ`K}A"NșM1I/AeހQתGF@A~eh-QR9C 5 ~d"9 0exp<^!͸~J7䒜t L䈝c\)Ic8E&]Sf~@Aw?'r3Ȱ&2@7k}̬naWJ}N1XGVh`L%Z`=`VKb*X=z%"sI<&n| .qc:?7/N<Z*`]u-]e|aѸ¾|mH{m3CԚ .ÕnAr)[;-ݑ$$`:Ʊ>NVl%kv:Ns _OuCX=mO4m's߸d|0n;pt2e}:zOrgI( 'B='8\L`"Ǚ 4F+8JI$rՑVLvVxNN";fVYx-,JfV<+k>hP!aLfh:HHX WQXt,:JU{,Z BpB)sֻڙӇiE4(=U\.O. +x"aMB[F7x"ytѫиK-zz>F>75eo5C9Z%c7ܼ%6M2ˊ 9B" N "1(IzZ~>Yr]H+9pd\4n(Kg\V$=]B,lוDA=eX)Ly5ot e㈮bW3gp : j$/g*QjZTa!e9#i5*j5ö fE`514g{7vnO(^ ,j~V9;kvv"adV݊oTAn7jah+y^@ARhW.GMuO "/e5[s󿬅`Z'WfPt~f}kA'0z|>ܙ|Uw{@՘tAm'`4T֠2j ۣhvWwA9 ZNU+Awvhv36V`^PK! ѐ'theme/theme/_rels/themeManager.xml.relsM 0wooӺ&݈Э5 6?$Q ,.aic21h:qm@RN;d`o7gK(M&$R(.1r'JЊT8V"AȻHu}|$b{P8g/]QAsم(#L[PK-![Content_Types].xmlPK-!֧6 0_rels/.relsPK-!kytheme/theme/themeManager.xmlPK-!g theme/theme/theme1.xmlPK-! ѐ' theme/theme/_rels/themeManager.xml.relsPK]  >e"',3n7:>EH1LOTV[y`*ekosv {} τ[)ʓܚ OJH=q`- j   !D!t!!!"4"d""""$#T####$D$t$$$%4%h%%% &9&m&&& '='q''' (A(u(( (n===XtC %')D_7   $$.. 3 $''''''+++++/333337~;~;~;;;?mCmCmCCCCxGxGxGGGKZOZOZOZOvOvOHSHSHSdSSRW([([([([D[D[___/_K_cgggg8g knnnnorvvvvvz~~~~~sssVVVr`777TpF4P"2׭׭׭յյù߹ooo}TTTq`222Nk=4P(6tttz KKKgU%%%A]-     #'''''+/////3c7c7c777k;>?>?>?>?Z?Z?-C-C-CICICGGGG5GQGKNNN O'ORVVVVVVZZZZZ^bbbbbfZjZjZjvjj`n.r.r.r.rJrJrvvvv+v+vyyyy W \\24!#)&(*;/h148;=?yANCvEFKEPQSV/YY\_GbdGgjlppux;{ ~5݃3PٍMϗ)şUv +=ѰnJ I|Hm74O9o$7J8  {]# %$&(),B.04A7Z8;?zADGJLOQ^U{WY[\_`vd8g|iykobp0twx3{~҈Қ}Pz:~,i)_JzCX'6*c>Q-n | C1` #'(,/y2368;)>qAICZEDHK|MPO),/157:;>@CGILNPRUWZ\^acfhjmoqtvz}   !#%'(*,-/124679;=>@BDEGIKLNPQSUWYZ\^`bcefhjkmoqrtvxy{}~  #VB>sJb"&%7()*-/1f46 8;<e>n?I@BOC@DEF9NP@Q=RRSTHUVbW[YY[ ^^_`pcdeghklosgvx zz{|v~5J؅++|K>eNZ k)š+՟U_bZ)vqް5Pb@C<i}7j42xr2y yf U$;(,/379h? @EGKOSW?[T_bfjnEov#w{~ׂĆz[ `>նsJU!,_l |$ `%'+/3'7Y;>CDKNv*+-.0234689<=?ABDEFHJKMOQSTVXY[]_`bdegiklnprsuwxy{|~   "$&)+.0358:<?ACFHJMORTVX[]_adgilnpsuwz|  !#}KRTgnp7>@RY[  !(*   & - / '''++++++333333;;;;;;{CCCCCCGGGGGGhOoOrOVS]S`SrSyS|S6[=[@[!_(_+_=_D_G_ggg*g1g4gnnno o ovvvvvv~~~~~~dknELObil&-0BIL$+. ǵεѵѹع۹}bil@GJ\cf%,/BIL (/2 Y`cu|3:=OVY   ''''''///q7x7{7777L?S?V?;CBCEC'G.G1GCGJGMGNOOO O#OVVVZZZZZZbbbbbbhjojrjjjj@lny{9Doq,.;=:<IK    ! MO13@B 13  hjuw(*<>JLUWz|4 6 *!,!j!l!!!$$$$%%-%/%_%a%%%%%%%&&''\(^(((++++,,////0 0222222 33L4N4X4Z4d4f4p4r444 5"5.50577777777y9{99999999999999999::::::::;;;;<<<<<<>>@@BBCC}EEEEEEEEFFFFFFFFBGDGNGPGyG{GGGGG H"H.H0HH I"I-I/IIILJNJ2K4K@KBKNKPKKKLLLLMM$M&M0M2M[M_MNNNNNNOOOOOOOOOOPPPPPPPPPP/Q:QVRXRRReSpSSSSSYT[TTTJULUWUYUdUfU2V4VlVnVVVVVYYZZ Z ZIZKZSZUZ[[u]w]^^^^'^)^3^5^\^^^h^j^v^x^aaaaaa)a+aaamcochhhhhhhhiiHiJi^i`itivi0k2kUkWkzk|kllwmymmmoooooooooo*p,pEpGpapcp}ppIqKqXqZqgqiq rrCrErsssssstt5t7tjtltQuSu}uuuuuuxxxxxx)x+xzzzzzzzzQ{S{`{b{m{o{|{~{{{{{{{{{V|X|~||||||||||P}R}d}f}~~KMY[ "-/SU`bmo @BbdoqɄ˄su|~ 6<cj܋ߋ #&(0368_esy׍ڍݍߍɏˏ؏ڏ,.;=IKWYegēƓ "CEOQ[]NP[]hj9;GISU`bmoz|˜ĘҘԘ8:XZfhΙЙ*,8:giuw@BMOZ\ϛћۛݛ  !#tvJU egrt +-8:EG"$rt,.ikvxӤդ XZikz|?AWYik_a<>JLgiuw9Dӫիحڭ{}ACgiòŲ}صڵ@B(*<>JLǹɹʺ̺24 $&ԿֿIKMOZ\gi*,8:FHTVWYfh[]ikuwhjy{#%02=?JLOQRTUWXZ[HHKHe~"#'((d),Z-2Y3;4s46d8g8};w zzSz ϐSV$'KH3333333333v{~ښܚNOOQRRTUWXZ[isuww&[^__xWXXfpqsEFT^pzZdu#1> %&(7D *+            !!!!!!!!!!!%w)))p-{---]5h5y555=@=Q=\=E E2E=ELL MMTTTT\\\\ddddullllVtatst~t4|?|Q|\|! + ̗חΟٟt[fw=HYd$5@al$/@K   vLWhs$%/%))*)5)000 18888@@HHKHv{~ښܚNOQRRTUWXZ[ww&[^__WXXsEFT^pzZdu#> D     !!!!%w)))p-{---]5h5y555=@=Q=\=E E2E=ELL MMTTTT\\\\ddddullllVtatst~t4|?|Q|\|! + ̗חΟٟt[fw=HYd$5@al$/@K   vLWhs$%/%))*)5)000 18888@@HHKH %r<l}HWn9bG0Jn}1J ?D3 @XGHFֻ@9ULvx!KNs Q+e_YP8`` K'iqkcX ^`OJQJo(*X pp^p`OJQJo(oX @ @ ^@ `OJQJo(X ^`OJQJo(X ^`OJQJo(oX ^`OJQJo(X ^`OJQJo(X PP^P`OJQJo(oX   ^ `OJQJo(^`OJPJQJ^Jo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(X>^`>o(&&^&`.L^`L.^`.^`.f!Lf!^f!`L.6$6$^6$`.''^'`.)L)^)`L.XX^X`OJPJQJ^Jo( ((^(`OJQJo(o ^`OJQJo(   ^ `OJQJo(   ^ `OJQJo(o hh^h`OJQJo( 88^8`OJQJo( ^`OJQJo(o ^`OJQJo((vv^v`o(vv^v`o(88^8`o(^`OJPJQJ^Jo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(hh^h`o(^`OJPJQJ^Jo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(h ^`OJQJo(*h ^`OJQJo(oh ` ` ^` `OJQJo(h 0 0 ^0 `OJQJo(h ^`OJQJo(oh ^`OJQJo(h ^`OJQJo(h pp^p`OJQJo(oh @@^@`OJQJo(^`OJPJQJ^Jo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(^`OJPJQJ^Jo( ^`OJQJo(o pp^p`OJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo(H^`CJOJQJo( 8^`OJQJo(-H^`CJOJQJo( @ @ ^@ `OJQJo( ^`OJQJo(o ^`OJQJo( ^`OJQJo( ^`OJQJo(o PP^P`OJQJo( hh^h`OJQJo(*(vv^v`>*o(n}1k9bG0K'i!KNGHF ? e_ @r<ULs Q}Wn8`)        i        Ʋ        )        )        )        )        vnH      -s >L&qh!8"mG c$ ,aZMVl-5 Z@'R$d^'\*c,^2|.3oz4Lqa6U7 B_9<y?#eADOI*OR~Ys\lo]yg^+b9abve9If]7po0s|Af{N}n?_0CVpp ubwdY]V=:Wu_ism|  ; J [ ]  p8 ]M  K v `3n=m 2SQG^.]j: ~7#X  ^3 na !""3'":"vO"U"Z"m #("$6&$&$9%Q%a%x&8&<'N'T'e'(j'!N(_`(Ag( )6) M*S*{*H+SM+u,"-Y-j.'/)/S`//0]0H^01f11R2Za2i2Q}23d3cX4651N5\[5 a5l5v5>77_k7K8N9:+:QN:Y:v:+;$=5=6={=>C@@@@WN@Mz@+AwBCNC/D5DfDE]ERRFmFGIGvGuIZYJ-cJ@K)!L[LeLtLxL;MNNNNNG"NL}N'+Ox>OrOwOPJP~P{ QxQ RaR6S/1S8SY$T 5T>T!UIUWW0W@Wa[WdW2X%Y-[4[na\o\*q\ ]!^H0^O^~^s4_W_g;`aAaY|a6 bm~cc:ldc6eX}eff(f flVfXff"-gRgnhhI h h^h@rh(i<jPkl}Ulnl~mwDmD7n;;non8o?oCoto&wo@yoKpqeqs{sz t2Stv6v3w9yJ0z;q{)|2|S|}-}i} ~&~%\~q~(9Yt9fP]Hko&l[r ^7xHT `,&mzhEE2"*LtulH=c)?UhT0y{\GuQHw&.m:||:I(@Q[n(5P;]`e@"8DD#cSs/CLj+}m9X4$e/|^>]wJ2M \ DW{H[n }UhGT qOh\i!%W'm[ ]}hu^7EN{OCOU1-y&Xg78C2)=5g$0$1/]rde12>RQ$EQZ! $ %2wU9+N0pa)UNf@iFEguUByh#dO_N H"HGjI%YKjk~ nMT<] V?9.bz57`..:U=gMirXrzIMk/{B4DG<^ /RF #d/ 1y+:5r=Lm@YnrX]Ahy!3(V]aw8L%COQ@zzzzL|?|@|B|CoGJH@H@L@0 @Unknown G.[x Times New Roman5Symbol3. .[x Arial7..{$ Calibri=Arial Bold5. .[`)TahomaC.,*{$ Calibri Light?= .Cx Courier New;WingdingsA$BCambria Math# h'CGwG 6iv6iv!4OqHX  ?22! xx܇] UDrugs: Contract Drugs List Part 1  Prescription Drugs (N through R) (drugs cdl p1c) drugscdlp1c_p00)Department of Health Care Services (DHCS)Mcclelland, Meghan (S&L HHS)L           Oh+'0 @X  < H T `lt|XDrugs: Contract Drugs List Part 1 Prescription Drugs (N through R) (drugs cdl p1c) ,Department of Health Care Services (DHCS)drugscdlp1c_p00tUpdates prior to 2015, refer to Version History JT pgs. 3, 20, 43, 44 (01.28.15) JT pgs. 6, 12 (02.25.15) JT pgs. 7-24 (03.30.15) JT pgs. 18, 29, 39, 40, 42 (04.29.15) JT pgs. 6, 13-19 (06.29.15) JT pgs. 13, 28, 29 (09.25.15) MiR pg. 17 (11.24.15) MiR pgs. 15-17 (12.28.15) JT pgs. 28-31, 37 (01.27.16) JT pgs. 30-33, 42 (02.25.16) JT pgs. 3-7, 12, 36, 39 (03.30.16) JT pgs. 13-26 (04.28.16) MiR pgs. 3-5, 8, 10, 27, 29, 38, 41, 43 (05.27.16) MiR pgs. 7, 21-30 (06.27.16) MiR pgs. 6, 8 (07.27.16) JT pgs. 13, 27 (08.29.16) MiR pgs. 2, 3, 5, 28 (09.27.16) MiR pg. 36 (10.26.16) JT pgs. 11, 12, 1532, 35, 36, 4143 (12.28.16) JT pgs. 3, 4, 12-19 (01.26.17) JT pgs. 5, 7, 25 (02.24.17) JT pgs. 1, 48, 10, 14, 17-21, 24, 26-44, 45-46 new (04.03.17) for March Pharmacy Priority MiR pgs. 7, 8, 10-15, 22, 40-44 (04.27.17) MiR pgs. 7, 10-12, 14, 15, 17-39, 42, 44 (05.26.17) JT pgs. 6-9, 40, 42-46, 47 new (06.28.17) JT pg. 39 (07.26.17) MiR pgs. 14-19, 44, 45 (08.29.17) JT pg. 12 (09.25.17) HC pg. 36 (11.27.17) MiR pg. 7 (12.27.17) SE pgs. 15-40 (04.24.18) SE pgs. 7-47, 48-52 new (06.28.18) SE pgs. 8-11 (08.29.18) MiR pgs. 23, 49 (09.26.18) HC pgs. 16, 43 (10.26.18) SE pg. 48 (11.28.18) LSa pgs. 4-52, 53 new (12.27.18) SE pg. 2 (01.29.19) TL pg. 17 (04.26.19) TL pg. 2 (06.26.19) TL pg. 15 (07.30.19) BA pg. 34 (08.28.19) AL pgs. 4-6, 19, 29-31, 35, 51-53 (11.27.19) HC pgs. 4-7, 51 (12.30.19) TL pgs. 35, 46-48, 53 (03.30.20) MM pgs. 35-42 (05.07.20) TL pg. 35 (05.28.20) TL pgs. 5-9, 35 (06.26.20) MM pgs. 19, 49-53, 54 new (07.29.20) MM pgs. 29, 39-44 (09.08.20) Correction for August Pharm Pri Normal.dotm Mcclelland, Meghan (S&L HHS)12Microsoft Office Word@ @xG@8v@606 ՜.+,D՜.+,@ hp  "CA-MMISvi VDrugs: Contract Drugs List Part 1 Prescription Drugs (N through R) (drugs cdl p1c) Titlet `-5Y!1=I U a  _dlc_DocId_dlc_DocIdItemGuid_dlc_DocIdUrlPublication CommunitiesProviderPublicationsTypeMonthDocument End Date Active YearHFFKTFNTSZSR-1460564009-202(d9a455d9-b33b-4d26-b523-45aa41779424https://sp.cammis.medi-cal.ca.gov/sites/DHCS/CA-MMIS/_layouts/15/DocIdRedir.aspx?ID=HFFKTFNTSZSR-1460564009-202, HFFKTFNTSZSR-1460564009-202;#ACU;#1(None)  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstvwxyz{|~Root Entry F0Data 1Table3WordDocument(SummaryInformation(uDocumentSummaryInformation8}MsoDataStore +00EFPU1EU4K0L==2+0+0Item  PropertiesOXLYCVOXYBWYIQ==2 +0+0Item  DProperties X3SYOA04JP2==2+00Item PropertiesSNPDVSSW==2+00Item %Properties@A5JXOOUWVSPR==2+00Item FPropertiesKUCompObjQr  !"#$&'()*+,-./0123456789:;<=>?ABCDEGHIJLMNOPRDocumentLibraryFormDocumentLibraryFormDocumentLibraryForm This value indicates the number of saves or revisions. The application is responsible for updating this value after each revision. metaAttributes"/> Document ID GeneratorSynchronous100011000Microsoft.Office.DocumentManagement, Version=16.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100021001Microsoft.Office.DocumentManagement, Version=16.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100041002Microsoft.Office.DocumentManagement, Version=16.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandlerDocument ID GeneratorSynchronous100061003Microsoft.Office.DocumentManagement, Version=16.0.0.0, Culture=neutral, PublicKeyToken=71e9bce111e9429cMicrosoft.Office.DocumentManagement.Internal.DocIdHandler   F Microsoft Word 97-2003 Document MSWordDocWord.Document.89q